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ABSTRACT  
The aim of the thesis is to investigate the regenerative potential of alternative sources of 
stem cells, derived from human dental pulp (hDPSCs) and amniotic fluid (hAFSCs) 
respectively, and, specifically to evaluate their capability to be committed towards the 
osteogenic and myogenic lineages, with the long-time objective to apply these stem cells to 
translational strategies in regenerative medicine for the repair of bone and skeletal muscle 
tissues. So far orthopaedic surgery, based on the use of conventional prosthesis and 
engineering biomaterials, does not represent a definitive solution in the treatment of some 
diseases, because the implanted material either does not offer the best histo-integration and 
does not replace the function of the original tissue.  
The tissue engineering approach could be therefore a promising tool to restore bone defects 
and deficiencies that currently are surgically treated through the application of artificial 
permanent implants. In particular, the in vitro bone production by stem cells may represent 
a radical breakthrough in the treatment of congenital or acquired pathologies and 
secondary traumas characterized by critical bone mass defects, which yet do not have any 
medical or surgical solution. Therefore, hDPSCs and hAFSCs were seeded and pre-
differentiated on different scaffolds to test their capability to subsequently reach the 
osteogenic differentiation in vivo, in order to recover critical size bone defects.  
Equine collagen, silk fibroin and P(d,l)LA were utilized to determine the best scaffold for 
hDPSCs and hAFSCs to undergo the effective osteogenic differentiation in vivo, to repair 
surgically operated parietal bone defects in rats. Results obtained in a recent study on 
ectopic implants allowed to identify fibroin scaffolds as a promising tool for osteogenic 
differentiation of human stem cells.  
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This study demonstrated that fibroin scaffold promotes mature bone formation and defect 
correction when combined to both hDPSCs and hAFSCs, in particular, with a higher bone 
amount produced by hAFSC-seeded scaffolds. 
Since the ultimate goal of cell-based therapy is to utilize new stem cell sources for clinical 
applications with minimal safety concerns, this study has investigated a culture condition 
that might allow human DPSCs to be used for human cell therapy in compliance with good 
manufacturing practices (GMPs). This study demonstrated that human serum (HS) is an 
appropriate supplement for the in vitro expansion of human DPSCs, since its addition to 
culture medium produced a good proliferation rate in comparison with the one evaluated 
after culturing the cells with foetal calf serum (FCS). As a matter of fact, human serum 
appeared to be an adequate additive to the osteogenic medium in order to achieve the 
expression of bone related proteins and induce the mineralization of the extracellular 
matrix by hDPSCs, in vitro.  Also, hDPSCs pre-differentiated towards the osteogenic 
lineage with the addition of HS showed a huge contribution in regenerating of the critical 
size bone defects in vivo.   
Similarly, cell-based therapy with hDPSCs and hAFSCs could represent an alternative 
therapeutic approach for patients with musculoskeletal traumas or diseases. This thesis 
investigated the ability of these stem cells to undergo the myogenic commitment in vitro 
by using different protocols, either when co-cultured with murine myoblasts (C2C12) and 
when differentiated alone after the demethylating treatment with 5-aza-2’-deoxycytidine. 
Human DPSCs and AFSCs, indeed, expressed under both these conditions regulatory 
factors and markers – such as myogenin and myosin - that are typical of the myogenesis 
process. Furthermore, after being pre-differentiated by means of demethylation, with or 
without the addition of conditioned media from differentiated C2C12, hDPSCs and 
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hAFSCs were tested for the capability to regenerate the damaged skeletal muscle of 
SCID/mdx mice, animal model of Duchenne Muscular Dystrophy (DMD). When injected 
into dystrophic muscles of SCID/mdx mice, pre-differentiated hDPSCs and hAFSCs were 
able to recover the skeletal muscle tissue, and more interestingly to restore dystrophin 
expression. These observations, altogether, suggest the eventual applicability of human 
DPSCs and AFSCs to translational strategies, in order to enhance the repair of injured 
skeletal muscle in DMD patients. 
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Introduction  
In Greek mythology, the Moirai also known in English as the Fates, and in Latin as the 
Parcae - euphemistically the "sparing ones" - were white-robed figures, personifying the 
inescapable destiny. Daughters of Zeus, they were three: Clotho (the spinner), who spun 
the thread the life from her distaff onto her spindle, Lachesis (the allotter), who measured 
the thread of life allotted to each person, and Atropos (the inexorable or inevitable), who 
was the cutter of the thread of life. Thus, they controlled the metaphorical thread of life of 
every mortal from birth to death.  
In medical research stem cells – whose definition derives from the Latin “stamen” – can 
be therefore metaphorically considered as the thread of life, namely the starting point from 
which the human being comes from.  
Actually, they have been demonstrated to carry out a fundamental role in maintaining, 
healing, regenerating and aging processes, therefore representing an adequate tool to be 
applied in regenerative therapies.  
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Tissue Engineering 
The primary goal of tissue engineering scientists is to optimize cell isolation, proliferation 
and differentiation of stem cells and to develop scaffolds and/or delivery systems that 
enhance the coordinated growth of three-dimensional tissues. The most used basic strategy 
consists in harvesting cells from a patient, expand them in cell culture, and seed them onto 
a scaffold that provides a biomechanical environment that leads the formation of the 
required tissue upon the production of a certain extracellular matrix by stem cells. The 
tissue can be grown on a scaffold that will completely resorb as the new tissue grows, so 
that only the new tissue will be implanted, or that will be gradually reabsorbed after 
implantation. Therefore, the tissue engineered complex must be able to survive, restore 
normal function, and integrate with the surrounding tissues (Polak and Bishop, 2006).  
 
Cell sources 
As a primary factor to achieve successful results in tissue engineering it is desirable and 
necessary to obtain a sufficient number of cells that show constantly an adequate 
phenotype and the ability to perform their specific biological functions, i.e. the correct 
organization of the extracellular matrix, the secretion of signaling molecules, and the 
interaction with the surrounding cells and tissues. Taken altogether, these functions are 
meant to enhance the repair (Polak and Bishop, 2006). 
 
Primary Cells 
These cells are tissue specific, are generally harvested from explant samples collected by 
surgical procedure. Primary cells are the most desirable with regard to immunological 
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compatibility, but they are differentiated and post-mitotic. When cultured ex vivo a de-
differentiation of the primary cells themselves as well as the development of an 
inappropriate phenotype might be observed. 
Moreover, functionality and proliferation rates tend to lower, and for the isolation of 
certain cell types, i.e. spinal cord neurons, the harvesting of primary cells is not 
recommended.   
These aspects have triggered the pursuit of alternative cell sources for tissue engineering 
approaches and stem cells actually provide solutions to some problems related to the use of 
primary cells (Polak and Bishop, 2006). 
 
Stem Cells 
Stem cells can be described as undifferentiated cells that are characterized by three 
fundamental abilities: proliferation, self-renewal, and differentiation towards multiple cell 
lineages (Polak and Bishop, 2006).  
They can be isolated from different sources, and with this regard are classified as 
embryonic stem cells (ESCs), foetal stem cells (FSCs), and adult stem cells (ASCs), whose 
range of differentiation potential may vary. Indeed, a more useful classification can be 
based on stem cells plasticity (Figure 1):  
 Totipotent are the most plastic ones and differentiate into any cell type, including 
placenta (i.e. the zygote and morula at 8-cells stage)  
 Pluripotent are the second most plastic stem cells after the totipotent ones, can 
differentiate into all cells, except for the totipotent and placental cells 
 Multipotent are the precursors of cells differentiated towards specific tissues 
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 Progenitor cells may differentiate into only one or a limited number of cell types, 
therefore are the least plastic cells  
 
              
 
 
Embryonic stem cells (ESCs) are the most plastic source available in tissue engineering. 
They were first described when they were isolated from the inner cell mass of a mouse 
blastocyst and then expanded in vitro (Evans and Kaufman, 1981; 3 Martin GR, 1981). 
ESCs have actually been demonstrated to be pluripotent, namely able to differentiate into 
all derivatives of the three primary germ layers: ectoderm, endoderm, and mesoderm (Nagy 
A et al, 1990; Bradley A et al, 1984; Xu RH et al, 2002). The murine ESCs were able to 
maintain an undifferentiated state while proliferating, and to differentiate towards all the 
mature somatic phenotypes, when stimulated with the appropriate signals. The initial 
isolation of murine ESC lines provided an easy model system to analyze the processes 
occurring during early development and cellular differentiation. These findings have also 
Figure 1: Stem cells classification by origin and plasticity  
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led the way to tissue engineering applications with similar pluripotent cells obtained from 
human blastocyst. As a matter of fact, human ESCs, were first derived in 1998 for 
infertility purposes (Thomson JA et al, 1998; Reubinoff BE et al, 2000); they show various 
discrete differences from murine ESCs, in fact they proliferate more slowly and most of 
them form flat, instead of spherical, colonies. Also, they can be dissociated in single cells 
more easily than their murine counterparts (Laslett AL et al, 2003).  
Because of their plasticity and potentially unlimited capacity for self-renewal, ESCs cell 
therapies have been proposed for regenerative medicine and tissue replacement in case of 
injury or disease. Diseases that might eventually be treated by ESCs cells include several 
blood and immune-system related genetic diseases, cancers, and disorders, type I diabetes, 
Parkinson's, blindness and spinal cord injuries. Nevertheless - beside the existing ethical 
controversy related to the use of embryonic stem cells - there is a huge concern with the 
possible transplantation of ESC into patients as therapies, because of the related possible 
formation of tumors, including teratoma (Knoepfler PS, 2009). Therefore, investigations 
have been carried out in order to find alternative solutions to ES cells. Takahashi and 
Yamanaka published a milestone manuscript in 2006 that defined a specific set of 
transcription factors capable of reverting differentiated cells back to a pluripotent status, 
thus creating induced pluripotent stem cells (iPS cells) (Takahashi and Yamanaka, 
2006): four key transcription factors - Oct4, Sox2, Klf4, and c-Myc - identified by 
screening 24 preselected mouse embryonic stem cell–specific factors were sufficient to 
reprogram adult mouse fibroblasts into embryonic stem cell–like iPS cells (Takahashi and 
Yamanaka, 2006). The same combination of transcription factors was demonstrated to be 
sufficient for the pluripotent induction of human cells as well (Takahashi K et al, 2007). 
Considering the convenience and reproducibility of generating iPS cells, experts have 
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raised the hope that iPS cells might accomplish much of the promise of human ESCs in 
regenerative medicine (Pera MF, 2008). Nonetheless, findings from different research 
groups have demonstrated that iPS cells injected into immunodeficient mice give rise to 
teratomas comprising all three embryonic germ layers, as similarly observed with ESCs. A 
further potential complication related to the use of iPS cells is the use of retroviral and 
lentiviral vectors to activate the necessary reprogramming transcription factors, in fact, 
even though much progress has been made in generating integration-free murine iPS cells, 
the safety of iPS cells needs to be rigorously tested, since all essential reprogramming 
factors are oncogenes, and their overexpression has been linked with cancers (Liu SV, 
2008). 
 
Foetal stem cells (FSCs) are the mesenchymal stem cells derived from the fetus. Recently, 
they have been isolated from foetal blood and raised the possibility of using autologous 
cell to treat fetuses in utero (Campagnoli C et al, 2001). 
The mesenchymal population obtained from foetal blood is characterized by adherent cells 
that divide upon 40 passages in culture and are able to differentiate towards the 
chondrogenic and osteogenic lineages, but also can form oligodendrocytes and 
hematopoietic cells. Furthermore, they are a unique source of stem cells since they can 
engraft into multiple organs and differentiate in a tissue-specific manner (Polak and 
Bishop, 2006).  
 
Adult stem cells (or postnatal somatic cells) are undifferentiated cells found among 
differentiated cells in a tissue or organ that can renew itself. These stem cells are located in 
a variety of tissues, including bone marrow, brain, liver, skin, and blood (Presnell SC et al, 
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2002). Their principal role is to maintain and repair the tissue they derive from. Although 
in a first moment they were considered to own a very limited differentiation potential, 
there has been much evidence that they show a considerable degree of plasticity, not 
without some debate about it (Hawley and Sobieski, 2002; Holden and Vogel, 2002; 
Verfaillie CM et al, 2002; Poulsom R et al, 2002; Raff M, 2003). Unlike ESCs, the 
application of adult stem cells in research and therapy is not considered to be controversial, 
since they do not require the destruction of embryos and can be accessibly obtained from 
adult tissue samples.  
In comparison with ESCs and FSCs, adult stem cells generally exhibit a lower 
differentiation potential and yield a more limited number of distinct progenitor cells. 
However, adult stem cells can significantly undergo proliferation and differentiation into 
more mature and tissue-specific cell types, according to changes in the specialized 
microenvironment where they reside - the niche - and the stem cell behavior is regulated 
through direct contact and paracrine signaling (Fuchs E et al, 2004; Niemann C, 2006; 
Wilson and Trumpp, 2006; Morrison and Spradling, 2008; Jones and Wagers, 2008).  
As mentioned above, stem cells are defined by their ability to produce more stem cells and 
also cells that differentiate. Stem cells can accomplish these two tasks by means of 
asymmetric cell division (Figure 2b), whereby each stem cell divides to generate one 
daughter with a stem-cell fate (self-renewal) and one daughter that differentiates 
(Betschinger and Knoblich, 2004; Clevers H, 2005; Doe and Bowerman, 2001; Yamashita 
YM et al, 2005). However, a limit of this division type is that stem cells would be unable 
to expand in number. Thus, asymmetric cell divisions cannot be the only explanation. Stem 
cells must have further self-renewal strategies that allow a dynamic control of their 
numbers: in fact, with symmetric divisions they can self-renew and produce differentiated 
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progeny (Figure 2c). Symmetric divisions are defined as the generation of daughter cells 
that are intended to acquire the same fate. Although the idea that stem cells can divide 
symmetrically may sound like a contradiction, stem cells are defined by their “potential” to 
generate more stem cells and differentiated daughters, rather than by their production of a 
stem cell and a differentiated daughter at each division. Therefore, when thought as a 
population, a pool of stem cells with identical developmental potential may generate only 
stem-cell daughters in some divisions and only differentiated daughters in others (Figure 
2d). Broadly, stem cells can rely either completely on symmetric divisions or on a 
combination of symmetric and asymmetric divisions (Morrison and Kimble, 2006). 
 
 
 
 
 
 
 
Figure 2: Stem cells (orange) must accomplish the dual task of self-renewal  and generation of differentiated 
cells (green); b–d: possible stem-cell strategies that maintain a balance of stem cells and differentiated 
progeny. b: asymmetric cell division; c: symmetric cell division; d: combination of cell divisions: each stem cell 
can divide either symmetrically or asymmetrically (Morrison and Kimble, 2006).  
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Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) can be found in bone marrow and in many other tissues. 
Bone marrow is a mesoderm derived tissue, basically constituted by elements from the 
stroma and the hematopoietic system, and is present in the interior of bones (Arai F et al, 
2004).  
For long time, it has been known that the bone marrow contains two types of stem cells, 
the hematopoietic stem cells (HSCs) – committed to differentiate towards mature blood 
cells – and the more undifferentiated stromal mesenchymal cells (MCs). 
The identification of the mesenchymal stem cell has so far depended on in vitro culture 
systems, which have provided very heterogeneous information on MSCs.  
They were identified through a combination of poorly defined physical, phenotypic, and 
functional properties. The first direct evidence that non-hematopoietic, mesenchymal 
precursor cells were present in the bone marrow derived from the research performed 
during the late 1960s by Friedenstein and colleagues:  bone marrow samples incubated in 
tissue culture flasks gave rise to a fraction of adherent cells within a few days, and soon 
after individual aggregates of 2 to 4 fibroblasts were observed, which could differentiate 
into cells able to form small deposits of bone or cartilage (Friedenstein AJ et al, 1976). 
These cells were called “colony forming unit-fibroblasts” or CFU-F. During the 1980s, 
several studies showed that cells isolated by the Friedenstein method were multipotent and 
able to differentiate towards osteoblasts, chondroblasts, adipocytes, and also myoblasts 
(Prockop DJ, 1997). The formation of CFU-F has been considered peculiar of 
mesenchymal stem cells, although a direct relationship between the two has not been 
clearly established, likely because of the high heterogeneity in morphology, cell size and 
differentiation potential observed among species and between colonies (Javazon EH et al, 
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2004). Caplan demonstrated that bone and cartilage turnover was mediated by MSCs, and 
the surrounding conditions were critical to inducing MSC differentiation (Caplan AI, 
1991). Later, the multilineage differentiation capability of MSCs was definitively 
demonstrated by Pittenger (Pittenger MF et al, 1999).  
The defining features of mesenchymal stem cells are inconsistent among scientists; to 
address this issue, the Mesenchymal and Tissue Stem Cell Committee of International 
Society for Cellular Therapy (ISCT) has recently proposed a set of standards to define 
human MSCs either for laboratory-based scientific investigations and for preclinical 
studies. First, MSCs must be plastic-adherent when maintained in standard culture 
conditions using tissue culture flasks. Second, ≥ 95% of the MSCs population must express 
CD105 (endoglin), CD73 (ecto-5’-nucleotidase) and CD90 (Thy-1), as determined by flow 
cytometry. Further, no more than 2% of these cells may express CD45 (pan-leucocyte 
marker), CD34 (hematopoietic progenitor and endothelial cell marker), CD14 or CD11b 
(monocyte and macrophage markers), CD79α or CD19 (B cell markers) and HLA-DR 
(marker of stimulated MSCs). Third, the cells must be able to differentiate towards 
osteoblasts, adipocytes and chondroblasts, under the standard differentiating conditions in 
vitro (Dominici M et al, 2006). 
MSCs embryologically derive from two major sources, neural crest and mesoderm, 
however these cells have been identified in not only mesoderm-derived but also endoderm- 
and ectoderm-derived tissues. Examples of tissues where MSCs have been characterized 
include, but are not limited to: mesodermal - bone marrow, trabecular bone, synovium, 
cartilage, fat, muscle, and tonsil; endodermal – thymus; ectodermal - skin, hair follicle, 
dura mater, and dental pulp; prenatal and perinatal tissues - umbilical cord, umbilical cord 
blood, amniotic fluid and placenta (Kuhn and Tuan, 2010).  
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Although still controversial, literature exists demonstrating the potential of MSCs to 
differentiate along non-mesodermal lineages, such as ectodermal skin and neurons and 
endodermal hepatocytes (Figure 3). MSCs are still correctly defined as “multipotent” 
rather than “pluripotent” despite these reports of their potential capability to differentiate 
into derivatives of all three germ layers.  
 
 
 
 
 
Most of the adult sources, including large volumes of normal bone marrow, are relatively 
difficult to access as a tissue source for the isolation of MSCs. Conversely, birth-associated 
tissues, including placenta, are readily and widely available. However, the bone marrow 
appears to be the most commonly exploited source of MSCs for most preclinical and 
clinical studies.  
Figure 3: Identification and characterization of mesenchymal stem cells. Cells with MSC-like characteristics have 
been isolated and from several adult tissues. The most common phenotypical markers are CD90, CD73, and CD105. 
MSCs have the capability to self-renew and exhibit multilineage potential into many mesodermal cell types. Other 
studies have described the potential of MSCs to differentiate into ectodermal and endodermal lineages. 
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It is necessary to highlight that although MSCs can be isolated from these different tissues 
and can develop into bone, cartilage, or fat, they are distinctive and reflects aspects 
peculiar to their tissue of origin: as a matter of fact, human pellets of MSCs from bone 
marrow have shown to be able to make cartilage extracellular matrix through chemical 
exposition to TGF-β (Johnstone B et al, 1998), while mesenchymal progenitors from adult 
fat require both TGF-β and BMP-6 in order to produce cartilage (Yoo JU et al, 1998; Estes 
BT et al, 2006).  
 
Dental pulp stem cells (DPSCs) 
Multipotent adult stem cells, as MSCs, are present in all mature tissues of the human body 
and are thought to reside in a specific area of each tissue where they may remain quiescent 
(non-dividing) for many years until they are activated by disease or tissue injury. MSC-like 
stem cells have been isolated – according to the standard criteria of mesenchymal stem 
cells illustrated above (Friedenstein AJ et al, 1976; Prockop DJ, 1997; Caplan AI, 1991; 
Pittenger MF et al, 1999; Dominici M et al, 2006) - from different tissue sources including 
bone marrow, adipose tissue, bone, periosteum, synovium of the joints, skeletal muscle, 
skin, pericytes of blood vessels, peripheral blood, periodontal ligament, umbilical cord, and 
dental pulp of permanent and deciduous teeth (Mizuno H et al, 2012).  
Lately, human dental pulp has been attracting interest for its ease of collection from 
permanent and deciduous teeth through minimally invasive and safe procedure.  
Dental pulp is a loose vascular connective tissue, surrounded by dentin (Figure 4) and 
consisting of a heterogeneous population of cells: the potential preodontoblasts, fibroblasts, 
stromal cells, endothelial and perivascular cells, neural cells and others (Pierdomenico L et 
al, 2005).  
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To date, multiple stem/progenitor cells have been isolated from human dental pulp, 
characterized, and classified. The postnatal stem cells first isolated from dental pulp were 
termed “dental pulp stem cells” (DPSCs) (Gronthos S et al, 2000). Besides this group, 
three more types of dental cell populations were  isolated and characterized: stem cells 
from exfoliated deciduous teeth (SHEDs) (Miura M et al, 2003), periodontal ligament stem 
cells (PDLSCs), dental follicle progenitor cells (DFPCs) (Morsczeck C et al, 2005) and 
stem cells from apical papilla (SCAPs) (Sonoyama W et al, 2008). 
In particular, stem cells from human dental pulp of impacted third molars (also known as 
“wisdom teeth”) show a greater advantage for the ease and low invasivity of recruitment, 
respect to the mesenchymal stem cells derived from bone marrow, adipose tissue, 
peripheral blood, and umbilical cord blood.  
Figure 4: The main structures of the tooth. Dental pulp is part 
of the center of the tooth, is contained within the pulp 
chamber and harbors vessels and nerves. 
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DPSCs are an attractive alternative source of mesenchymal stem cells since they show a 
wide panel of favorable properties:  
- Easy surgical access and low invasiveness for the patient: the extraction of one or 
more molars, in healthy individuals, is a widespread and routinary procedure 
among the population. 
- Very low morbidity of the anatomical site after the collection of the pulp.  
- High efficiency of the extraction procedure of the stem cells from the pulp tissue.  
- Minimal tooth processing may be required for banking of samples with no 
immediate plans for DPSC expansion and use, which subsequently would limit 
costs and favor the clinical banking of these cells.  
- Cells expanded in culture can be preserved and stored for at least six months, and 
likely longer, at −85°C with regards to the qualitative ability to differentiate in at 
least a tri-lineage manner. Therefore, they can be cryopreserved, retaining multi-
differentiation potential (Graziano A et al, 2008). 
- No teratomas have been observed after in vivo transplantation. 
- Mesenchymal stem cells from the dental tissue have been shown to possess 
immunosuppressive properties. These findings have elicited further interest in these 
cells as alternative cell sources able to modulate alloreactivity and tissue 
regeneration, following transplantation into human leukocyte antigen-mismatched 
donors (Wada N et al, 2013). 
 
Dental pulp embryogenesis 
In vertebrate embryos, a group of cells, called neural crest (NC) cells, separate from the 
neural tube and migrate to re-aggregate with other cells. In the developing embryo, almost 
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all organs, glands, and tissues - such as craniofacial skeleton, cornea, teeth/dentin, thyroid 
gland, thymus, cardiac septa, adrenal gland, melanocyte, autonomic nerve, sensory nerve, 
and Schwann cells - have these basic cells (Crane and Trainor, 2006; Alberts B et al, 2008; 
Lee G et al, 2010). The contribution from NC cells in building of the head of vertebrates 
has been considered to be a turning point in the evolution of the vertebrates (Gans and 
Northcutt, 1983). Although NC cells are of ectodermal origin, it has been suggested to call 
them “mesectoderm” or “ectomesenchyme”, since they undergo “mesenchymalization.” 
This property is important with regard to mesenchymal stem cells, since their origin is the 
mesenchyme, which is derived from the mesodermal germ layer. On the other hand, along 
with the cranial skeleton and other tissues of head and neck, odontoblasts and tooth 
papillae are derived from mesectoderm, or ectomesenchyme (Le Douarin NM et al, 2004). 
Oral ectomesenchymal and ectodermal interactions phylogenetically precede the origin of 
odontogenesis (Moss ML, 1969). 
During the sixth week of embryogenesis, the ectoderm covering the stomodeum starts to 
proliferate, giving rise to the dental laminae. Reciprocal interactions between ectoderm and 
mesoderm layers lead to placode formation. One of these thick, ovoid ectodermal 
structures develops into tooth germs, where cells, belonging to the neural crest, will 
differentiate into the dental germ, containing both dental papilla and follicle. Therefore, 
dental pulp is made of ecto-mesenchymal components, containing neural crest-derived 
cells, which display plasticity and multipotential capabilities (Sinanan AC et al, 2004). 
Pulp is externally separated from dentin by odontoblasts and by Hohl’s subodontoblastic 
cells, that are pre-odontoblasts (Goldberg and Smith, 2004). Adjacent to this layer, the pulp 
is rich in collagen fibers and poor in cells. Then, another, more internal layer, contains 
progenitor cells and undifferentiated cells, some of which are considered stem cells (Jo YY 
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et al, 2007). From this layer, undifferentiated cells migrate to various districts where they 
can differentiate under different stimuli and make new differentiated cells and tissues. The 
final, innermost layer is the core of the pulp; this area comprises the vascular plexus and 
nerves. Up to more recent discoveries (Gronthos S et al, 2000; D’Aquino R et al, 2007), 
researchers hypothesized that DPSCs were present in this layer (Fitzgerald M et al, 1990). 
Actually, only undifferentiated perivascular cells can be found in it. 
The third molar tooth germ begins development around the sixth year of life. Until this 
time, embryonic tissues of dental lamina remain quiescent and undifferentiated within the 
jaw of the child. Even though crown mineralization begins during the eighth year of life, 
often third molar roots are still incomplete at the age of 18. This means that the structure of 
those teeth is still immature at this age, and a conspicuous pool of undifferentiated cells, 
resident within the “cell rich zone” of the dental germ pulp, are needed for development. 
 
DPSCs characterization 
During the characterization of these newly identified dental stem cells, certain aspects of 
their properties have been compared with those of bone marrow mesenchymal stem cells 
(BMMSCs). 
Differences have been noted between the dental stem cell populations and BMMSCs.  
One important feature of pulp cells is their odontoblastic differentiation potential. Human 
pulp cells can be induced in vitro to differentiate into cells of odontoblastic phenotype, 
characterized by polarized cell bodies and accumulation of mineralized nodules 
(Tsukamoto Y et al, 1992; About I et al, 2000; Couble ML et al, 2000). DPSCs isolated 
with enzyme treatment of pulp tissues form CFU-Fs with various characteristics (Gronthos 
S et al, 2000; Huang GT et al, 2006a). Colonies show different cell densities, suggesting 
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that each cell clone may have a different growth rate, as reported for BMMSCs (Gronthos 
S et al, 2002). Within the same colony, different cell morphologies and sizes may be 
observed also. If seeded onto dentin, some DPSCs convert into odontoblast-like cells with 
a polarized cell body and a cell process extending into the existing dentinal tubules (Huang 
GT et al, 2006a; Huang GT et al, 2006b). In addition to their dentinogenic potential, 
subpopulations of hDPSCs also possess adipogenic and neurogenic differentiation 
capabilities, by exhibiting adipocyte- and neuronal-like cell morphologies and expressing 
respective gene markers (Gronthos S et al, 2002). More recently, DPSCs were also found 
to undergo osteogenic, chondrogenic and myogenic differentiation in vitro (Laino G et al, 
2005; Zhang W et al, 2006; D’Aquino R et al, 2007). 
Current evidence suggests that biochemical pathways involved in the differentiation of 
DPSCs into functional odontoblasts are similar to differentiation pathways of BMMSCs 
into osteoblasts (Shi S et al, 2001): odontoblasts and osteoblasts express similar 
mineralized matrix proteins, such as dentin matrix protein 1, fibronectin, collagen type I, 
alkaline phosphatase, osteonectin, osteopontin, bone sialoprotein, and osteocalcin 
(Nakashima M et al, 1994; Shiba H et al, 1998; Kuo MY et al, 1992; Tsukamoto Y et al, 
1992; Buurma and Rutherford, 1999). Therefore, DPSCs actually share a similar pattern of 
protein expression with BMMSCs in vitro.  
To date, dental-tissue-derived stem/progenitor cells have been used for tissue engineering 
studies in large animals to assess their potential in pre-clinical applications (Sonoyama W 
et al, 2006; Liu Y et al, 2008).  
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Amniotic fluid stem cells (AFSCs) 
 
 
 
 
Since decades, cells from cord blood, amniotic fluid, and the chorion were used in 
perinatal medicine mainly for invasive diagnostic purposes, such as detection of foetal 
infections, rare metabolic diseases, and mainly foetal karyotyping. With the introduction of 
the use of umbilical cord stem cells for the treatment of haematologic diseases many years 
ago, a new future for the use of perinatal cells has begun, namely the use of perinatal 
(amniotic, placental, chorionic, umbilical) stem cells for therapeutic purposes.  
In normal pregnancies, amniotic cells can be collected by amniocentesis, between 16
th
 and 
18
th
 week of gestation. In routine amniocentesis 16-20 ml of amniotic fluid are commonly 
sampled (Figure 5). 
Figure 5: amniotic fluid aspiration during amniocentesis at 16-18 weeks of 
gestation. 
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Amniotic fluid contains heterogenous population of cells, which are contributed mainly 
from the foetal skin, and possibly from placenta as well. Amniotic fluid-derived stem cells 
(AFSCs) have shown physical characteristics of both embryonic and adult stem cells.  
According to their morphological and growth characteristics, amniotic fluid cells can be 
classified into three types: epithelioid, amniotic-fluid specific, and fibroblastoid (Milunsky 
A, 1979).  
The first evidence of human amniotic fluid containing stem cells came from Prusa et al. in 
2003. They identified Oct-4 expression in human amniotic fluid and proposed that human 
amniotic fluid might be a new source for pluripotent-like stem cells without raising any 
ethical debates associated with human embryonic stem cells (Prusa AR et al, 2003). In the 
same year, In’t Anker et al. demonstrated that human amniotic fluid was an abundant 
source of foetal MSCs, and these cells exhibited a phenotype and multilineage 
differentiation potential that appears to be similar to that of BMMSCs. They suggested that 
these AF-derived MSCs could be used in co-transplantation together with umbilical cord 
blood derived hematopoietic stem cells (In’t Anker PS et al, 2003). In 2004, Tsai MS et al. 
successfully isolated AF-derived MSCs using a new two-stage culture protocol, and their 
study showed that these cells could be expanded rapidly and maintained the ability to 
differentiate towards multiple cell types, such as adipocytes, osteoblasts and neurons in 
vitro (Tsai MS et al, 2004). Following, in 2007, Atala and colleagues isolated the c-kit 
(CD117) positive population by immunoselection, from second trimester amniotic fluid 
samples and demonstrated that AFSCs are “broad-spectrum multipotent” (that is, 
pluripotent) - similarly to embryonic stem cells - and can differentiate into adipogenic, 
osteogenic, myogenic, endothelial, neurogenic, and hepatic lineages, including the 
representatives of all three germ layers (De Coppi P et al, 2007).  
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AFSCs isolation 
Currently, there are three main techniques for the isolation of AFSCs from human amniotic 
fluid. The first one is the direct culture from native amniotic fluid obtained from 
amniocentesis specimens, as described by In’t Anker et al. (In’t Anker PS et al, 2003). The 
second one is the immunoselection, through the use of magnetic beads, of the c-kit positive 
cell population from amniocentesis samples, which allowed to sort cells that are easily 
expandable in culture as stable lines (De Coppi P et al, 2007). The third one is a two-stage 
culture protocol performed by Tsai et al. using non-adhering amniotic fluid cells (NA-
AFCs) of the primary culture to isolate AFSCs without interfering with the ordinary 
procedure of foetal karyotyping (Tsai MS et al, 2004): in this protocol, NA-AFCs are 
collected from the supernatant of primary amniocytes in culture (first stage) in serum free 
Chang’s medium (Chang and Jones, 1985), then these NA-AFCs are plated for the 
expansion of AFSCs after completing the foetal chromosome analysis (second stage). The 
main difference of this protocol, compared to the other two, is that it isolates the non-
adhering cells which had been left without any added nutrition for 7 to 10 days, a condition 
similar to serum deprivation that might enhance the expression of some embryonic genes 
by the stem cells (Pochampally RR et al, 1994). 
 
AFSCs characterization  
The AFSCs are positive for HLA I antigens (HLA-ABC), and negative for HLA II 
antigens (HLA-DR, DP, DQ).  
AFSCs are negative for markers of the hematopoietic lineage (CD45) and of hematopoietic 
stem cells (CD34, CD133). Nevertheless, AFSCs also show phenotypic characteristics 
similar to those of MSCs derived from other sources, such as umbilical cord blood, 
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placenta and first-trimester foetal tissues (blood, liver and bone marrow), which are 
positive for SH2, SH3, SH4, CD29, CD44, and CD166, and are negative for CD10, 
CD11b, CD14, CD34, CD117 and EMA (Colter DC et al, 2001; Pittenger MF et al, 1999; 
Young HE et al, 2001). Most importantly, AFSCs show the expression of Oct-4 mRNA 
and Oct-4 protein, a transcription factor expressed by embryonic cancer cells, embryonic 
stem cells, and embryonic germ cells, thus reflecting a key role in the maintenance of 
pluripotency of mammalian stem cells, in vitro and in vivo (Cogle CR et al, 2003; 
Henderson JK et al, 2002; Jiang Y et al, 2002). 
Therefore, it is clear that human amniotic fluid contains a subpopulation of stem cells 
characterized by a high potential, that arise from embryonic and extra-embryonic tissues 
during the process of foetal development and growth. 
The AFSCs can be expanded rapidly and can maintain the capability to differentiate 
towards multiple cell types in vitro. As mentioned above, their expression of the 
transcription factor Oct4 suggests that they represent an intermediate stage between 
pluripotent ESCs and lineage-restricted adult stem cells (De Coppi P et al, 2007). 
It was observed indeed that AFSCs are able to differentiate along adipogenic, osteogenic, 
myogenic, endothelial, neurogenic and hepatic pathways. The acquisition of lineage-
specific functionality was shown by AFSCs differentiated in vitro toward neurons, 
osteoblasts and hepatocytes. Unlike ESCs, AFSCs do not form tumors in vivo (De Coppi P 
et al, 2007). 
Based on these findings, amniotic fluid may provide a promising alternative source for 
investigation of human “broadly multipotent” stem cells without raising the ethical 
controversies correlated with embryonic stem cells. 
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Bone regeneration  
 Bone composition  
Bone is a dynamic, highly vascularized connective tissue with the unique capacity to heal 
and remodel, depending on the line of stress (Jayakumar and Di Silvio, 2010). Bone is 
constituted by cells and an extracellular mineralized matrix within which the majority of 
cells are contained. Osteoblasts, along with osteocytes, osteoclasts, cells of the 
neurovascular supply, and cells of the periosteum, endosteum, and marrow, constitute the 
cellular component of bone (Jayakumar and Di Silvio, 2010). 
Osteoblasts are cells originally derived from osteoprogenitor cells of mesenchymal origin 
located in bone marrow and connective tissues. They are responsible for forming bone by 
generating, secreting, depositing, and mineralizing bone matrix. Osteoblasts contain active 
cytoskeletal proteins for maintaining of their structural integrity as well as to facilitate 
motility and attachment to surfaces. Their contact interactions with the surrounding 
osteoblasts and osteocytes at intercellular gap junctions are achieved by the extensions 
created by their plasma membranes. Osteoblasts primarily synthesize and secrete organic 
matrix, predominantly collagen type I and trace quantities of collagen type V as monomers 
that undergo extracellular configuration as triple helical procollagen. They produce a 
variety of other factors and glycoproteins and also express genetic markers. 
Osteoblasts deposit a premineralized bone matrix, osteoid, and subsequently facilitate its 
mineralization. The mineralization process involves supersaturation of extra-cellular fluids 
at local zones and increased osteoblastic alkaline phosphatase (ALP) activity, which raises 
local calcium and phosphate concentrations.  Osteoblasts also produce osteocalcin, which 
binds calcium, further concentrating local calcium levels. 
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Osteocytes are essential bone maintenance cells derived from osteoblasts and are 
surrounded by newly formed osteoid matrix; they are spread within matrix, helping to 
preserve it, but are not as active as osteoblasts in the generation of osteoid and mineralized 
matrix. 
Osteoclasts are the primary cells involved in bone resorption, by causing demineralization. 
They are specialized in local removal of bone during growth and during remodeling of 
osteons and bone surfaces. Osteoblastic formation and osteoclastic resorption are two sides 
of a finely “coupled” process in normal bone. 
Premineralized matrix laid down by osteoblasts occurs in the early stages of bone 
formation. Osteoblasts produce most of the organic components of matrix, including 
collagenous and non-collagenous matrix components. Collagen synthesized by osteoblasts 
polymerizes from tropocollagen, at extracellular level. The molecular structure of collagen 
in bone is more covalently crosslinked than in other connective tissues, and crosslinking 
progresses with maturation, making the configuration stronger. Non-collagenous matrix 
components include proteoglycans, matrix proteins, growth factors, and cytokines. These 
complex macromolecules attach to collagen fibers and bone crystals. Among the non-
collagenous matrix proteins are osteocalcin, osteonectin,  osteopontin, and 
thrombospondin. Osteocalcin is required for the bone mineralization, by binding calcium 
and hydroxyapatite, and is a specific marker of bone formation. Osteonectin is a 
phosphorylated protein which binds to collagen and hydroxyapatite, and may be a factor in 
cell adhesion and initiating the crystallization of hydroxyapatite. Osteopontin and 
thrombospondin are bone sialoproteins and bind to integrins on osteoclasts, mediating their 
adhesion to bone surfaces before taking resorptive action. 
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Undifferentiated MSCs form osteoprogenitor cells which subsequently form osteoblasts in 
low-strain and high-oxygen-tension environments. Osteoprogenitor cells are also located in 
periosteum, endosteum, and Haversian canals and are in a standby state, ready for a 
stimulus to proliferate and differentiate into osteoblasts before forming bone (Jayakumar 
and Di Silvio, 2010).  
 
 Osteoblastogenesis regulation and bone related proteins expression 
Bone formation is a tightly regulated process which is characterized by a sequence of 
events starting by the commitment of osteoprogenitor cells, their differentiation into pre-
osteoblasts and in mature osteoblasts whose function is to synthesize the bone matrix that 
becomes progressively mineralized. Osteoblast commitment, differentiation and function 
are all governed by several transcription factors, resulting in expression of phenotypic 
genes and acquisition of the osteoblast phenotype (91 Marie, 2008). 
Runx2 (CBFA1) has been identified as the major transcription factor controlling osteoblast 
commitment and differentiation. It is a member of the Runt family of transcription factors, 
is expressed by mesenchymal cells at the onset of skeletal development and is present in 
osteoblasts throughout their differentiation (Marie PJ, 2008). Molecular studies and genetic 
manipulation of Runx2 in vivo indicated that the expression of Runx2 is both necessary 
and sufficient for mesenchymal cell differentiation towards the osteoblast lineage 
(Karsenty and Wagner, 2002; Komori T, 2006). As a member of the Runx family of 
transcription factors, Runx2 operates in bone lineage cells by binding to the Runx 
consensus sequence (PuACCPuCA), first named the osteoblast specific element. 
The Runx regulatory element can be found in the promoter of all major osteoblast genes 
controlling their expression, including type I collagen alpha 1 chain, osteopontin, bone 
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sialoprotein and osteocalcin, resulting in the establishment of an osteoblast phenotype. In 
addition, Runx2 was found to negatively control osteoblast proliferation by acting on the 
cell cycle (Pratap J et al, 2003). 
Recent studies indicate that Runx2 interacts with several regulatory proteins within the 
nuclear architecture, resulting in activation or repression of genes which control the 
program of osteoblast proliferation and differentiation (Stein GS et al, 2004). This 
indicates that Runx2 can control osteoblastogenesis through multiple mechanisms. 
Molecular and genetic studies revealed that Osterix (Osx) is a zinc finger transcription 
factor specifically expressed by osteoblasts which is important for osteoblast 
differentiation. Osx-deficient mice show absence of osteoblasts and defective bone 
formation (Nakashima K et al, 2002). However, Runx2 is expressed in Osx-deficient mice, 
indicating that Osx acts downstream of Runx2. 
Osx transcription is positively governed by Runx2 (Celil AB et al, 2005) and acts by 
directing pre-osteoblasts to immature osteoblasts. Although little is known on the 
mechanisms of action of Osx, this protein was found to form a complex with the nuclear 
factor of activated T-cells (NFAT), resulting in activation of COLIA1 promoter activity 
(Koga T et al, 2005). Accordingly, constitutive activation of NFAT activates the Wnt 
signaling pathway, bone formation and bone mass (Winslow MM et al, 2006). 
Significantly, Osx modulate the expression of important osteoblast proteins such as OPN, 
OCN, bone sialoproteins and Col I. Osteopontin (OPN) - also known as secreted 
phosphoprotein-1 (SPP1), urinary stone phosphoprotein, uropontin, and early T-cell 
activator (ETA-1) - is a highly conserved multifunctional phosphorylated glycoprotein 
which is expressed in many mineralized and soft tissues including bone, dentin, elastin, 
muscle, tumors, and in body fluids (milk, inner ear, and urine). It is also a major 
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component of the calcium carbonate–containing eggshell (Gericke A et al, 2005). In bone, 
OPN is produced by osteoblastic cells at various stages of differentiation, by differentiated 
osteoblasts and osteocytes, and also by osteoclasts. Studies on the temporal expression of 
OPN during the formation of bone in vitro and during the formation of intramembranous 
and endochondral bone in vivo, have revealed a pattern in which OPN is produced early in 
the osteogenic differentiation, in immature osteoblasts (McKee and Nanci, 1995), and then 
it is progressively down-regulated according to its role of mineralization inhibitor during 
the bone development (Hunter GK et al, 1996).  
Osteocalcin (OCN) is the major bone-specific protein, produced by mature osteoblasts, 
and it is expressed only post-proliferative phase, during the differentiation of normal 
diploid osteoblasts, when mineralization of extracellular matrix occurs. OCN is the most 
abundant non-collagenous protein that constitutes 1-2% of the total bone protein or 20% of 
the non-collagenous protein, and is the seventh most abundant protein of the human body. 
The biological function of OCN has been correlated with bone turnover, and it has been 
used as a biochemical marker for the clinical evaluation of bone metabolism. Transcription 
of the OCN gene is controlled by modulatory organized basal regulatory sequences and 
hormone responsive enhancer elements: these include the TATA box, which contain 
sequences for glucocorticoid receptor binding.  
Interestingly, many growth factors were found to control osteoblastogenesis by modulating 
transcription factors expression or activity. Notably, bone morphogenetic protein (BMP)-2 
promotes Runx2 expression in mesenchymal osteoprogenitors and osteoblastic cells (Lee 
KS et al, 2000; Lee MH et al, 2003a; Haÿ E et al, 2004). BMP2 also promotes Osx and 
Dlx5 expression in osteoblastic cells (Miyama et al, 1999; Lee MH et al, 2003b). Although 
transforming growth factor – β (TGF-β) was found to inhibit Runx2 activity in vitro (Kang 
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JS et al, 2005), TGF-β promotes bone formation in vivo by increasing Runx2 and 
decreasing PPARγ2 expression (Ahdjoudj S et al, 2002). Another anabolic factor, insulin-
like growth factor-1, promotes Osx in osteoblastic cells (Celil and Campbell, 2005). The 
anabolic factor fibroblast growth factor-2 (FGF-2) increases Runx2 phosphorylation and 
activity (Kim HJ et al, 2003). Consistently, activation of fibroblast growth factor receptor 2 
(FGFR2) expression or signaling results in increased Runx2 expression and enhanced 
osteoblast differentiation (Guenou H et al, 2005; Chen L et al, 2003; Tanimoto Y et al, 
2004). 
 
 Tissue engineering as a novel approach for bone healing 
The majority of bone lesions, such as fractures, heal well under standard conservative or 
surgical therapy. Severe bone defects can be treated through bone grafting, distraction 
osteogenesis, or the use of bone-replacing materials. 
The basis of the understanding of bone regeneration are some fundamental principles.  
Osteoinduction is the ability to induce bone formation by attracting and stimulating bone 
forming cells of the recipient. This phenomenon features in most of bone healing 
processes, and osteoinductive materials provide a biological stimulus for induction, 
recruitment, stimulation, and differentiation of primitive, undifferentiated, and pluripotent 
stromal cells into osteoblasts or preosteoblasts, the initial cellular phase of a bone-forming 
lineage. Osteoinductive materials include autografts, demineralized bone matrix, and 
specific BMPs that naturally form bone within the skeleton as well as extra-skeletally 
(Hotz and Herr, 1994).  
Osteoconduction describes the capacity of a material to guide bone-forming tissue from 
the periphery to a given defect. Osteoblasts from the edges of the defect that is being 
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grafted use the bone graft material as a framework upon which to spread and generate new 
bone, by taking advantage of the composition, shape, and surface texture of the graft 
material. Examples of exclusively osteoconductive biomaterials are hydroxyapatites 
(Cornell and Lane, 1998). 
Osteogenic materials are defined as those that contain living cells and are capable to form 
bone. 
Osseointegration is the process of achieving stable direct anchorage and contact between 
bone and implant. This process was first described by Brånemark as “direct structural and 
functional connection between ordered, living bone and the surface of a load-carrying 
implant” (Brånemark PI, 1983). 
 It has also been defined at the histological level as the direct anchorage of an implant by 
formation of bone tissue around the implant without the growth of fibrous tissue at the 
bone–implant interface. 
Nowadays, despite the current therapeutic measures, large bone defects, due to traumas, 
infections or cancer, represent a primary problem in orthopaedic, trauma and craniofacial 
surgery. Autologous bone grafting is currently considered as the ‘gold standard’ for 
osteogenic bone replacement (118 Gazdag AR et al, 1995). It is highly efficient in filling 
defects, even under problematic conditions. However, the use of autologous bone grafts is 
limited by a significant donor-site morbidity, and by the need for vascularization which 
increases with the amount of bone transplanted. Moreover, bleeding, haematoma, 
infection, and chronic pain are common complications of bone-graft harvest, and occur in 
up to 30% of such procedures (Hill NM et al, 1999; Seiler and Johnson, 2000). 
Allogenic bone can also be used for the repair of bone defects when autologous bone grafts 
are not available (Gazdag AR et al, 1995). The initial biomechanical properties resemble 
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the autologous bone grafts, but the allogenic bone is not osteogenic and, therefore, is less 
efficient in bone formation than the autologous bone. 
Lastly, synthetic materials are mainly used as bone cements, in fact they are widely used 
for the fixation of total joint prosthesis and for craniofacial bone defects. Nevertheless, 
these materials are neither degraded nor integrated over time, hence long-term results are 
not always satisfying. 
Bone tissue engineering is a state-of-the-art science designed to overcome the issues 
related to the conventional approaches. A successful bone tissue engineering requires a 
well coordinated interaction between cells, growth factors, and scaffold biomaterials in 
order to produce a skeletal tissue environment that is biologically and mechanically 
consistent with the original. MSCs have been widely used in experimental bone tissue 
engineering and currently hold promise for fracture repair and treatment of critical mass 
bone defects, osteoporosis, tumours, osteonecrosis (Panetta NJ et al, 2009; Lee K et al, 
2009; Gordeladze JO et al, 2009; Clines GA, 2010; Bernstein P et al, 2009; Abdallah and 
Kassem, 2008; Oreffo and Triffitt, 1999). 
In particular, in vitro expanded MSCs are commonly combined with a scaffold complex in 
order to be implanted at a given site, and the choice of the scaffold type itself relies on the 
site of application.  
While materials intended for implantation were in the past designed to be “bio-inert”, the 
focus has been recently shifted toward the design of deliberately ‘bioactive’ materials that 
integrate with  biological molecules or cells and regenerate tissues (Langer and Vacanti, 
1993; Hench and Polak, 2002). In the case of  bone, optimal materials should preferably be 
both osteoinductive, osteoconductive and capable of  osseointegration.  
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Many bone substitute materials intended to replace the need  for autologous or allogeneic 
bone have been evaluated over the last two decades. In general, they consist of either 
bioactive ceramics, bioactive glasses, biological or synthetic polymers, and composites of 
these (Hench and Polak, 2002; Kretlow and Mikos, 2007; Liu and Czernuszka, 2007). The 
ideal basic premise, if following the tissue engineering  paradigm, is that the materials will 
be resorbed and replaced over time  by, and in tune with, the body’s own newly 
regenerated biological tissue (Langer and Vacanti, 1993).  
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Substitutes for foetal bovine serum as supplements to culture 
media  
Recently, researchers and clinicians have addressed great interest on the identification of 
the  optimal conditions for cell culture medium. The development of techniques to grow in 
vitro human mesenchymal stem cells, and the deeper understanding of cell differentiation 
pathways have expanded the horizon of prospective therapeutical applications. The level of 
concern about potential contamination and damage to cells/tissues depends on how and 
how much they have been handled and manipulated. When stem cell-based products 
involve more than minimal manipulation - such as expansion or differentiation - the cells 
are usually grown in in vitro culture, and the standard culture medium contains bovine 
serum. This common process, which involves the use of non-human serum, may be the 
source of possible contamination or immune reaction to foreign proteins, such as 
xenogenic bovine serum antigens, underlining the necessity for a more careful evaluation 
of culture media. 
Foetal bovine or calf serum (FBS and FCS, respectively) are the most widely used growth 
supplements for cell culture, primarily because of their high levels of growth stimulatory 
factors and low levels of growth inhibitory factors. At the moment, most isolation and 
expansion protocols for clinical scale production of stem cells use culture media frequently 
supplemented with FCS, which may contain potentially harmful xenogeneic compounds. 
In particular, bovine serum proteins may be internalized in stem cells stimulating 
immunogenicity (Martin MJ et al, 2005; Spees JL et al, 2004); consequently, 
immunological reactions may occur due to the bovine protein attachment to cells in culture 
that act as antigenic substrates once transplanted (Heiskanen A et al, 2007). A wide variety 
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of polypeptides contained in bovine serum may attach to cells, inducing significant 
metabolic/morphologic changes; for example, bone marrow derived mesenchymal 
progenitor cells show a different behavior in culture performed in the presence of FCS with 
or without heat inactivation (Bruinink A et al, 2004); a significant antibody response to 
bovine lipoproteins is observed using autologous T cells grown in FCS-supplemented 
medium (Tuschong L et al, 2002), linked to the observation that FCS contains a low 
density lipoprotein, which, in turn, binds to its human receptor (Haylett and Moore, 2003). 
These evidences allow to assume that FCS is unsuitable for the culture of stem cells to be 
used in cellular therapy, suggesting that cell culture medium composition should not 
include animal products (Dimarakis and Levicar, 2006; Sekiya I et al, 2002). 
Several studies are in progress in order to define safer culture conditions for stem cells, 
indeed it is believed that the serum replacement medium should ideally be replaced by one 
containing only human proteins, hormones and growth factors. 
Cultivation in serum-free conditions has demonstrated contradictory results, and no 
breakthroughs have yet been reached. In particular, some studies revealed that human 
MSCs from bone marrow and umbilical cord blood were efficiently ex vivo expanded in 
serum-free medium (Liu CH et al, 2007;  Pochampally RR et al, 2004). Nevertheless, 
additional studies demonstrated that serum-free media cannot promote human MSCs 
growth without the addition of cytokines and/or growth factors (Gronthos and Simmons, 
1995; Kuznetsov SA et al, 1997), likely due to the fact that serum induces intracellular 
calcium oscillations, which are vital to stem cell proliferation and differentiation (Foreman 
MA et al, 2006).  
Using human blood derivatives should eliminate or reduce the risk of secondary effects 
due to FCS constituents. Various human plasma derivatives have been purposed as 
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alternatives to FCS to supply nutrients, adhesion and growth factors. These alternative 
supplements include autologous or allogenic human serum, human plasma, human platelet 
lysates and their released factors (Schallmoser K et al, 2007; Stute N et al, 2004; 
Kocaoemer A et al, 2007). 
In the last years platelet-rich plasma was largely used to grow and differentiate MSC but 
its role in MSC osteogenic differentiation is debated (Feng Y et al, 2010; Gruber R et al, 
2006; Tomoyasu A et al, 2007). Human platelet lysate and platelet-rich plasma have been 
shown to be suitable culture supplements to replace FCS, for the expansion and in vitro 
osteogenic differentiation of hDPSCs (Lee UL et al, 2011; Govindasamy V et al, 2011). 
Apart from human plasma, in which have been identified factors that might be relevant for 
the differentiation of adipocyte precursor cells (e.g., growth hormone and insulin) 
(Sypniewska G et al, 1987), many studies have focused the attention on the use of 
autologous serum. Several papers evidenced that autologous serum/plasma preserves the 
differentiation capacity, promotes a greater cell amplification, and enhances motility of 
stem cells, improving cellular and genetic therapies (Shahdadfar A et al, 2005; Oreffo RO 
et al, 1997; Yamamoto N et al, 2003; Stute N et al, 2004; Lin HT et al, 2005; Kobayashi T 
et al, 2005; Gregory CA et al, 2006; Mizuno N et al, 2006); evidence in favour of using 
autologous serum exists for the expansion of human bone marrow MSCs, indeed it results 
as effective as supplementing the culture medium with FCS, and cells appear 
transcriptionally more stable over many cell doublings (Shahdadfar A et al, 2005). On the 
other hand, autologous serum might be a scarcely available or qualitatively affected source, 
particularly in the case it must be taken from some classes of patients, such as children, 
elderly, anaemic and with ongoing inflammatory processes individuals (Tateishi K et al, 
2008).  
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Therefore, allogenic human serum, potentially from blood type AB healthy donors, might 
be investigated as a preferable alternative to autologous serum for the expansion and 
differentiation of human MSCs. 
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Skeletal muscle regeneration 
 Structure of skeletal muscle  
Skeletal muscles are composed of multinucleated myofibers organized into fascicles that 
are grouped together to form individual muscles. Individual myofibers develop by end-to-
end fusion of mononucleate myoblasts to form a multinucleate syncytium. Each 
mononucleate cell is a contractile unit known as sarcomere, bounded by Z discs, that is, 
structures anchoring the actin filaments into each end of the sarcomere. The sarcomere 
shortens when the actin filaments slide along the thick myosin filaments toward the middle 
of the sarcomere (Ham and Cormack, 1987; Alberts B et al, 2008). Each myofiber is 
wrapped by endomysium, multiple myofibers are organized into fascicles surrounded by 
perimysia, and the fascicles collectively constitute the muscle, which is surrounded by an 
epimysium (Figure 6). 
     
Figure 6: a. skeletal muscle structure; b. contractile unit of a myofibril. 
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Skeletal muscles are highly vascularized within and between the mysial sheaths and are 
heavily innervated at specialized contacts called neuromuscular junctions. At their ends, 
muscles grade into fascia or tendons, which attach them to bone. Fibroblasts of the 
endomysium synthesize an extracellular matrix consisting of a typical basement membrane 
made of fibronectin, laminin, and collagen IV that surrounds each myofiber, as well as 
collagen I and sulfated proteglycans outside the basement membrane, including a muscle 
specific sulfated proteoglycan (Caplan AI, 1991). In addition, the endomysium synthesizes 
tetranectin, a protein that acts as an interactive agent with other extracellular matrix 
proteins, cell surface receptors, cytokines, and proteases (Wewer UM et al, 1998). 
Tetranectin binds sulfated polysaccharides, suggesting that it might interact with the GAG 
chains of proteoglycans. It is particularly prominent at myotendinous junctions, which are 
considered to be the equivalent of focal adhesion sites in muscle (Wewer UM et al, 1998). 
The actin cytoskeleton of the myofibers is linked to the extracellular matrix by a 
dystrophin-glycoprotein complex (DGC), a multi-subunit complex comprised of 
intracellular dystrophin and syntrophins, and three types of sarcolemmal proteins: 
dystroglycans, sarcoglycans, and sarcospan. Disruption of this linkage by mutations in 
dystrophin or the sarcoglycans results in sarcolemmal damage during contraction, 
rendering the myofibers susceptible to necrosis, which is a feature of muscular dystrophy 
(Cohn RD et al, 2002). 
 
 Muscle development (myogenesis)  
In vertebrates, muscle development occurs in three distinct phases: embryonic, fetal and 
postnatal. During embryonic development, muscle progenitors are derived from somites, 
which are compartmentalized into dermomyotomes (giving rise to skeletal muscle and 
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parts of the dermis) and sclerotomes (from which bones and ribs are derived). Expression 
of the paired-box/homeodomain transcription factors Pax3 and Pax7 marks myogenic stem 
and progenitor cells within the developing dermomyotome (Kassar-Duchossoy L et al; 
2005; Relaix F et al, 2005). These Pax3/7-positive cells initiate expression of muscle 
regulatory factors (MRFs), including Myf5 (myogenic factor 5) Mrf4 (Myf6), MyoD 
(Myod1, myogenic differentiation 1) and Mef2c (myogenic enhancer factor 2C), which 
drives progenitors to the muscle lineage (Rudnicki MA et al, 1993; Edmondson DG et al, 
1994; Kassar-Duchossoy L et al, 2004). Subsequently, the muscle progenitors exit the cell 
cycle, express the transcription factor myogenin and fuse to form multinucleated myotubes 
(Buckingham and Vincent, 2009). At late fetal stages, Pax3/7-positive cells relocalize to a 
specific microenvironment adjacent to muscle fibers under the basal lamina (Kassar-
Duchossoy L et al, 2005). These cells, which originate from the Pax3/7 positive cells of the 
dermomyotome, persist in a quiescent state in the adult, where they are known as satellite 
cells (SC) and marked by continued expression of Pax7 (Seale P et al., 2000; Schienda J et 
al., 2006) (Figure 7). 
 
 
 
 
 
Figure 7. During myogenesis Pax3
+
Pax7
+
 muscle progenitor cells (MPCs) give rise to undifferentiated MyoD-positive 
myoblasts. Further fusion of myoblasts generates multinucleated myofibers expressing differentiation markers such 
as myosin heavy chain (MHC), MyoD and myogenin. The basal lamina adjacent to differentiated myofibers acts as a 
niche for satellite cells during postnatal myogenesis. DM, dermomyotome (figure revised from Koch U et al, 2013). 
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Recent studies have shown that Pax7-positive satellite cells exhibit SC properties as they 
give rise to viable muscles when transplanted into the tibialis anterior muscles of 
Pax7DTR/– mice (Sambasivan R et al, 2011). Moreover, these cells are crucial for muscle 
regeneration: injury drives quiescent satellite cells back into the cell cycle, inducing 
myoblast proliferation and differentiation, and hence regeneration of lost muscle fibers. 
During this process, new satellite cells are formed to replenish the SC pool and ensure 
muscle cell homeostasis (Sambasivan and Tajbakhsh, 2007; Brack and Rando, 2012).  
Injured muscle tissue fails to regenerate following ablation of Pax7-positive satellite cells, 
highlighting the role of these cells in muscle regeneration (Sambasivan R et al, 2011). 
 
 Molecular mechanisms modulating satellite cells: quiescence, activation, 
replenishment  
The activation of satellite cells is a multistep process. Ultimately, the activating signals 
received by quiescent satellite cells lead to the transition from G0 to G1 phase of the cell 
cycle, i.e. exit from the quiescent state. Once the satellite cells have entered into their first 
cell cycle, they proceed through a highly proliferative intermediate progenitor stage, 
characterized by high levels of Pax3 expression (Conboy and Rando, 2002). From this 
stage, the cells progress to the myoblast stage, thus completing the lineage progression 
from the quiescent, undifferentiated progenitor to the cell that will undergo myogenic 
differentiation and fusion. 
A primary candidate for inducing satellite cells to break quiescence is the hepatocyte 
growth factor (HGF)–c-met pathway as HGF is present in an inactive form in the 
extracellular matrix surrounding satellite cells and c-met is expressed on quiescent satellite 
cells (Cornelison and Wold, 1997; 149 Tatsumi R et al, 1998). However, several factors, 
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both in vivo and in vitro, stimulate satellite cells and might serve as redundant pathways. 
Different members of the fibroblast growth factor (FGF) family are present in muscle 
tissue and released upon injury (Johnson and Allen, 1995), and various FGF receptors, 
notably FGF-R1 and FGF-R4, are expressed by quiescent satellite cells (Cornelison DD et 
al, 2001; Kästner S et al, 2000). The activation of the Notch signaling pathway is also 
important for satellite cell activation as inhibiting Notch signaling prevents satellite cell 
activation and proliferation (Conboy and Rando, 2002). This pathway is activated in 
muscle in response to injury by the upregulation of the Notch ligand, Delta-1, thus 
activating the Notch receptor that is expressed on satellite cells and inducing cell 
proliferation. One particularly intriguing finding is that Delta is upregulated on myofiber 
membranes distant from a muscle injury site (Conboy IM et al, 2003), and this could 
explain the “activation at a distance”, that has been long recognized to be a property of 
satellite cells (Schultz and McCormick, 1994).  
It is likely that the satellite cell niche is not only important in maintaining quiescence but 
also in determining the kinetics of satellite cell activation. This might be particularly 
relevant to the effect of aging on satellite cell activation. It has long been known that 
satellite cells isolated from aged animals display a delay of cell cycle entry in vitro 
(Schultz and Lipton, 1982). However, once activated, the cells proliferate normally. 
Furthermore, the age-related decline in satellite cell activation can be modified by extrinsic 
influences (Conboy IM et al, 2003; Conboy IM et al, 2005), indicating that the cellular 
environment profoundly influences the behavior of quiescent satellite cells. These findings 
suggest that the age-related decline in tissue regenerative capacity might not be due to 
irreversible changes in satellite cells but, rather, to modifiable changes in the stem cell 
niche. Once activated, satellite cells undergo rapid proliferation and progress along a 
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myogenic lineage. The proliferative expansion of the intermediate progenitor population - 
characterized by declining levels of CD34 and high levels of Pax3 expression - is strongly 
regulated by the Notch signaling pathway (Conboy and Rando, 2002). Inhibition of Notch 
signaling induces exit from this progenitor stage to the myoblast stage, and constitutively 
high levels of Notch signaling maintain cells in the intermediate progenitor stage.  
The number of satellite cells in an adult muscle remains relatively constant through 
repeated bouts of injury and regeneration (Schultz and McCormick, 1994), thus assuring a 
sufficient reserve for future needs (Schultz, 1996). It has long been assumed that 
replenishment comes from the ability of satellite cells to self-renew. Although direct 
evidence has been lacking, in a recent publication, definitive evidence of satellite cell self-
renewal was demonstrated by the transplantation of single fibers with their associated 
satellite cells from one mouse strain to another (Collins CA et al, 2005): using a genetic 
lineage marker, the donor satellite cells were shown to expand and generate new satellite 
cells in the host, adopting the appropriate anatomical position, expressing the appropriate 
biochemical markers and, most importantly, mediating subsequent regenerative responses 
in the host. The molecular mechanisms that regulate satellite cell self-renewal remain to be 
determined.  
One interesting question concerning the transition of myogenic progenitor cells from a 
proliferative state to G0 phase is the role of MyoD expression. The levels of MyoD 
fluctuate through the cell cycle, with the highest levels observed during G1, where it can 
trigger differentiation in a mitogen-poor environment (Kitzmann M et al, 1998). Given the 
strong ability of MyoD to induce myogenic differentiation, it is clear that there are potent 
inhibitory activities that maintain the cells in a proliferative state in the presence of high 
levels of MyoD (Zhang JM et al, 1999). If proliferative signals are present, MyoD is kept 
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inactive (Wei and Paterson, 2001), the progression to S phase and the loss of signal-
responsiveness follow, and MyoD expression declines. On the contrary, in response to 
differentiation cues during G1, cells exit the cell cycle, MyoD levels increase, and the 
differentiation-inducing activity of MyoD becomes evident with the upregulation of key 
targets, such as the cyclin-dependent kinase inhibitor p21, cyclin D3, Rb and myogenin, 
that combine cell cycle exit to tissue-specific gene expression (Kitzmann and Fernandez, 
2001). The increase of MyoD, myogenin and other MRFs initiates the terminal myogenic 
differentiation program by upregulating genes such as those encoding creatine kinase, 
myosin heavy chain and acetylcholine receptor subunits that underlie the functional 
properties of mature muscle (Hawke and Garry, 2001). Hence, withdrawal from the cell 
cycle during differentiation represents a transition that assures both irreversible arrest and 
myogenic differentiation. On the other hand, the entry in G0 phase, following quiescence-
inducing stimuli, does not involve either irreversible arrest or myogenic differentiation. In 
this case, MyoD declines instead of increasing, and there is no induction of MyoD 
differentiation-inducing activity or targets such as p21, Rb, or other MRFs (Milasincic DJ 
et al, 1996; Sachidanandan C et al, 2002). A general conclusion is that there is a different 
constellation of growth-suppressive molecules in reversibly, versus irreversibly, arrested 
cells. 
 
 Muscular dystrophy  
Muscular dystrophy is a diverse set of genetic myopathies characterized by progressive 
muscle weakness, atrophy, and replacement of myofibers by fat and scar tissue (Bushby K, 
2000; Burton and Davies, 2002). Several forms of the disease are caused by mutations in 
components of the dystrophin-glycoprotein complex (DGC), which links the cytoskeleton 
47 
 
of the myofiber to the basement membrane. The DGC plays an important role in protecting 
the sarcolemma against muscle contraction-induced injury. There are three mouse models 
of muscular dystrophy, the dystrophin-deficient mdx mouse, the β or γ sarcoglycan-
deficient (SGD) mouse, and the muscle creatine kinase-dystroglycan (MCK-DG) null 
mouse, in which the dystroglycan gene is inactivated by a Cre-lox construct driven by the 
MCK promoter (Cohn RD et al, 2002). All these models maintain muscle mass by 
regeneration from satellite cells during the early stage of the disease, but since the SCs 
carry the genetic defect as well, the regenerated mdx and SGD mouse myofibers are 
dystrophic too. Eventually the muscles exhaust their pool of SCs and become fatty and 
fibrotic (Cossu and Mavilio, 2000; Heslop L et al, 2000).  
Recent achievements in the treatment strategy for DMD - which affects nearly 1 in 3000 
male births annually - have been encouraging. Clinical trials for exon skipping have 
yielded promising results in several dystrophic patients (Wood MJ et al, 2010); however, 
studies attempting muscle stem cell engraftment have been notably disappointing in the 
clinical scenario (Skuk and Tremblay, 2011). 
Failure of satellite cell integration into the dystrophic or diseased muscle could be 
attributed to the limited ability of the human tissue to home grafted cells, an event that 
probably does not occur in experimental murine models for dystrophies, where the 
implanted satellite cells not only just integrated and produced myofibers in the 
degenerative tissue, but also led to the production of dystrophin protein which was 
intrinsically lacking in the mdx mice. Importantly, the grafted satellite cells also yielded 
donor-derived satellite cells in the engrafted muscle, proving their stem cell ability of self 
renewal and niche establishment (Sacco A et al, 2008; Cerletti M et al, 2008; Partridge TA 
et al, 1989). The fairly poor yield of functional muscle in clinical studies following cell 
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replacement has been also proposed to be due to loss of stemness by satellite cells 
expanded in culture systems, a consequence that appear to be related to their dependence 
on their niche (Cosgrove BD et al, 2009). Recent findings demonstrated that satellite cells 
cannot currently be isolated and expanded in vitro since they rapidly differentiate into 
myoblasts, the more committed muscle precursors marked by the irreversible expression of 
Myf5, MyoD, and myogenin (Boonen and Post, 2008). Another issue in such therapeutic 
settings is the small amount of satellite cells that can be collected versus the difficulty of 
grafting several hundreds of muscles all over the body. 
Initial clinical trials with allogeneic myoblasts injection into the muscles of non-
immunosuppressed DMD patients indicated a transient restoration of dystrophin positive 
fibers and improvement of muscle strength, which then was lost (Law PK, 1982; Huard J 
et al, 1992; Karpati G et al, 1993; Mendell JR et al, 1995; Gussoni E et al, 1992; 
Beauchamp JR et al, 1997).  
Reasonably, the limits emerged from these therapeutical approaches, have triggered 
extensive research over the years. One of the attempted approaches has been to transplant 
bone marrow cells into the dystrophic muscle (Saito T et al, 1995; Ferrari G et al, 1998; 
Gussoni E et al, 1999): the bone marrow MSCs  showed indeed the capacity to 
differentiate into muscle, and were also reported to be non-immunogeneic, since they do 
not constitutively express MHC class II antigens or the T-cell co-stimulatory molecule B7 
(McIntosh and Bartholomew, 2000). More recent studies have allowed to identify several 
cell sources that may act as potential muscle stem cells, either within the muscle tissue 
itself or in other tissues (Mitchell KJ et al. 2010; Sampaolesi M et al. 2003; Torrente Y et 
al. 2006). 
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1.1 In vivo implantation of stem cells-scaffold constructs 
 
Cell isolation from human dental pulp and amniotic fluid 
Cells were isolated from dental pulp as formerly described by Laino et al. (Laino G et al, 
2006). Human dental pulp was extracted from third molar or permanent teeth of adult 
subjects after informed consent of patients undergoing routine extractions. Dental pulp was 
removed from the teeth and then immersed in a digestive solution (3 mg/mL type I 
collagenase plus 4 mg/mL dispase in α-MEM) for 1 h at 37°C. Once digested, pulp was 
dissociated and then filtered through 100 μm Falcon Cell Strainers to obtain a cell 
suspension. Cells were then plated in Petri dishes and cultured in culture medium (α-MEM 
with 20% FBS, 100 μM 2P-ascorbic acid, 2 mM L-glutamine, 100 U/ml penicillin, 100 
μg/ml streptomycin; all from Invitrogen), at 37°C and 5% CO2.  
Supernumerary amniocentesis samples were collected with informed consent of the 
patients according to Italian law and ethics committee guideline. Amiotic fluid stem cells 
were isolated as previously described by De Coppi et al. (De Coppi P et al, 2007): backup 
human amniocentesis cultures were harvested by trypsinization. 
After isolation, the cells obtained from human dental pulp (hDPSCs) and amniotic fluid 
(hAFSCs)  underwent magnetic cell sorting by using MACS technology (Miltenyi Biotec) 
and the STRO-1
+
 hDPSCs and c-kit
+
 hAFSCs sub-populations were obtained.  
Following the immune-selection, hDPSCs and hAFSCs were expanded in the culture 
medium described above.  
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Preparation of fibroin scaffolds 
Sponges with randomly distributed pores have been produced by solvent casting 
particulate leaching starting from fibroin water solution, as follows. Bombyx mori cocoons 
purchased from Cooperativa Sociolario were degummed by treating twice with 1,1 g/l 
Na2CO3 water solution at 98°C for 1 h, washing in deionized water, and air-drying. After 
degumming, silk was dissolved in 9.3M (20% w/v) LiBr (Sigma-Aldrich) at 65°C for 2 h. 
To eliminate LiBr, the solution was then dialyzed in a Slide-ALyzer Cassette (Pierce; 
MWCO3500 Da) against distilled water for 3 days; the fibroin concentration was afterward 
adjusted to 8% w/v. Silk fibroin scaffolds were prepared by adding 8 g of granular NaCl 
(particle size ≈ 315–425 µm) into 4 ml fibroin solution, and then poured in cylindrical 
polystyrene plates (3,5 cm in diameter and 1.5mm in height). The containers were covered, 
left at room temperature (RT) for 24 h in order to induce gelation, and then immersed in 
deionized water for 3 days with water change every 6 h in order to remove the salt (Wang 
Y et al, 2010). All samples were sterilized by Cobalt-60 gamma rays using facilities and 
control procedures validated in conformity with UNI EN ISO 9001, UNI EN ISO 13485, 
UNI EN ISO 11137, and GMP by Gammarad Italia S.p.A. with a standard cycle of 25.00 
kGy and a dosimeter batch Red Perspex 4034.  
 
Scaffold’s physical characterization 
Environmental scanning electron microscopy. The morphology of the silk fibroin scaffolds 
was evaluated using the Field Emission-Scanning Electron Microscope (FE-SEM) SUPRA 
40 (Zeiss Company). Samples were completely dried at RT and gold sputtered before 
analysis. Images were acquired at 2 kV. 
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Water content and open porosity  
For water absorption evaluation, three specimens of each material were cut in disks (1 cm 
in diameter), weighed in dry state (Mdry), and then immersed in distilled water for 2 days at 
RT. 
Samples were then blotted dry on filter paper to remove excess water and weighed (Mwet). 
The percent water content, Wwater referred to the weight of the wet sample, was calculated 
as: 
        
           
    
      
 
The open porosity of the SF sponges was quantitatively evaluated on three samples using 
the principle of liquid displacement. Hexane (n-Hexane; Sigma-Aldrich) was used, since it 
is able to permeate the completely submerged fibroin scaffold without swelling. The 
scaffold was immersed in a known volume of hexane V1 in a graduate cylinder for 10 
minutes. The volume V2 of the hexane and the sponge was measured. Finally, the sponge 
was removed and the residual volume of hexane V3 was registered. The total volume of the 
scaffold can be obtained as follows: V= (V2 -V1) + (V1 - V3) =V2 -V3, where V2 -V1 is the 
volume of the bulk structure of the sponge and V1 -V3 is the volume of the hexane retained 
in the open porosity of the scaffold. The porosity can be calculated from the following 
equation: 
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This ratio measures the percentage of the free volume of the scaffold with respect to the 
total volume of the scaffold. 
 
Cell seeding on fibroin scaffolds 
 Discs with a height of 1,5mm and diameter of 13mm were cut from fibroin scaffolds and 
placed in 24-well tissue culture plates. All the scaffolds were then washed twice with 
culture medium (1 h for each rinse). Cells were seeded on each scaffold at density of 1500 
cell/mm
3
 and cultured for 24 h with 2 ml of culture medium. After 24 h culture medium 
was replaced by osteogenic medium (culture medium supplemented with 10% FBS, 100 
nM dexamethasone, 10mM β-glycerophosphate, and 50 µg/ml ascorbic acid-2-phosphate; 
all from Sigma-Aldrich). Cells/scaffolds cultures were then maintained in osteogenic 
medium  for 10 days in an incubator at 37°C with 5% CO2, in order to obtain a cell 
population committed to osteogenic differentiation yet still able to proliferate. Some 
samples were stained with 6-CFDA (Sigma-Aldrich) to test the viability of seeded cells. 
 
Surgery and transplantation procedure 
To study the bone-forming ability of hAFSCs and hDPSCs on fibroin scaffolds, a critical-
size bone defect was obtained by a full-thickness dissection of both the internal and 
external tables of compact bone and the trabecular diploe constituting the parietal skeletal 
segment, according to previous studies (de Mendonça Costa A et al, 2008; Kim J et al, 
2007). Constructs were then implanted into a critical-size parietal defect up to 4 weeks 
(Figure 8 and Table 1). None of the animals died of infection or any other complication. 
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Table 1. Description of the treatment groups of impant. 
 Left parietal Right parietal 
I group  (5 rats) Fibroin Fibroin + DPSC 
II group (5 rats) Fibroin Fibroin + AFSC 
III group (5 rats) Bone defect None 
 
In this study outbred male Sprague-Dawley rats with age ranging between 12 and 14 weeks 
(Charles River Laboratories) were used. The animals were anesthetized with an 
intraperitoneal injection (0,2 ml/100 g of body weight) of ketamine hydrochloride (5%). A 
midline skin incision was performed from the nose-frontal area to the external occipital 
protuberance. 
The skin and underlying tissues, including the periosteum, were reflected laterally to 
expose the full extent of the calvaria. Two symmetric full-thickness cranial defects of 5 x 
8mm size were done on each parietal region of 15 animals by a micromotor drill under 
constant irrigation with sterile physiological solution to prevent overheating of the bone. 
The underlying dura mater was undisturbed (Figure 8). One scaffold of 5 x 8 x 1.5mm size 
Figure 8. Cranial defects (5 x 8mm) induced in the parietal cranial bones in the rat with (B) or 
without (A) cell/scaffold implant. 
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was implanted into each cranial defect and adapted to fill the entire defect area (Figure 8). 
Each animal received two constructs except for the animals of group III. After the scaffold 
implantation, the incisions were sutured with prolene 4-0 sutures (Ethicon). Animals were 
immunocompromised by means of Cyclosporine A at a dosage of 15mg/kg body weight 
(b.w.), administered 4 h before transplantation and then daily for 2 weeks. 
During the last 2 weeks the daily dosage was reduced gradually up to 6 mg/kg b.w. Four 
weeks later the rats were sacrificed and the calvarias were rapidly explanted and fixed in 
4% paraformaldehyde in phosphate-buffered saline (PBS) for 3 h. All animal procedures 
were performed according to the guidelines approved by the Committee of Use and Care of 
Laboratory Animals of the University of Modena e Reggio Emilia. 
 
Radiography 
Explanted calvaria samples were radiographed by a Kodak RVG Digital Radiography 
Systems. 
 
Histology 
Fixed samples were decalcified in 0,5M EDTA (pH 8.3), then rinsed in PBS, dehydrated 
with graded ethanol, diaphanized, and embedded in paraffin. Transversal serial sections 
(10 µm thick) were cut through the parietal bones containing the implants. Routine 
hematoxylin/eosin (H&E) staining was performed in order to analyze the morphological 
details. Images of histological samples were obtained by a Zeiss Axiophot microscope 
equipped with polarizer filters and with a Nikon DS-5Mc CCD color camera. 
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Confocal microscopy 
Histological sections were processed as previously described (Maraldi T et al, 2009). 
Mouse anti-human mitochondria (Millipore) diluted 1:100 in PBS containing 3% bovine 
serum albumin (BSA) for 1 h at RT was used as primary antibody (ab). Secondary ab was 
diluted 1:200 in PBS containing 3% BSA (sheep anti-mouse-FITC; Jackson Immuno 
Research). After washing in PBS samples were stained with 1 µg/ml DAPI in PBS for 3 
minutes and then mounted with anti-fading medium (0,21 M DABCO and 90% glycerol in 
0,02 M Tris, pH 8.0). Negative controls consisted of samples not incubated with the 
primary Ab. 
Confocal imaging was performed on a Leica TCS SP2 AOBS confocal laser scanning 
microscope as previously described. The confocal serial sections were processed with 
ImageJ software to obtain 3D projections (Maraldi T et al, 2009). The image rendering was 
performed by Adobe Photoshop software. 
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1.2 Human serum for osteogenic differentiation of human DPSCs 
Preparation of human serum 
 
Human serum was obtained from a blood collection by healthy male volunteers who 
underwent written informed consent. The whole blood was drained into 8 ml tubes 
containing silica beads for clot activation (Greiner Bio-one), then was stored at room 
temperature for 3 hours and centrifuged at 1400 x g for 15 minutes, to separate 
erythrocytes and coagulum contents. The collected serum was heat inactivated at 56°C for 
30 minutes, then filtered with a 0,22 µm syringe-driven filters units (Millipore). Aliquots 
of sterile human serum were stored at – 20°C. 
 
Cell culture 
 
Human dental pulp was extracted from the enclosed third molar of teenage subjects 
undergoing a routine tooth extraction, after written informed consent of their parents. 
Human DPSCs were isolated from dental pulp, as described above. Briefly, cells obtained 
from dental pulp were plated at clonal density (1,6 cells/cm
2
) and after 6 days of culture, 
nodules originated by single cells were isolated from the culture plate, re-plated and 
expanded. The STRO-1
+
 hDPSC sub-population was obtained by magnetic cell sorting 
(MACS; Miltenyi Biotec) using an anti-STRO-1 antibody (Santa Cruz). Two different 
culture media were used during isolation steps and throughout the subsequent cultures: α-
MEM supplemented with heat inactivated 10% Foetal Calf Serum (FCS-medium; 
Euroclone) or Human Serum (HS-medium), 2 mM L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin, at 37°C and 5% CO2. 
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Cell counting 
The proliferation rate was analyzed on the same hDPSCs population, seeded in 60 mm 
Petri dishes at the density of 4000 cells/cm
2
 and cultured for 1 week until reaching the 
confluence. Cell counting was performed in three culture conditions: serum free culture 
medium; culture medium supplemented with FCS; culture medium supplemented with HS. 
Each day cells were stained with CFDA (6-Carboxyfluoresceine diacetate; Sigma Aldrich) 
vital dye to detect viable cells and observed by using a Nikon TE2000 inverted microscope 
with a 10x objective. For each experimental point, green fluorescent cells contained in 10 
fields of 1 mm
2
 were counted. The mean of cell number was calculated on three 
experimental samples for each condition and cell density was expressed as mean of 
cells/cm
2
 ± standard deviation (SD). The population doubling time (PDT) was calculated 
in the phase of exponential growth by the following formula:    
 
     
            
                      
  
 
N7d is the cell number at day 7 and N1d is the cell number at day 1. To determine the 
population doubling (PD) rate, hDPSCs were initially seeded at the density of 4000 
cells/cm
2
 in culture medium supplemented with FCS or HS. Cells were passaged and 
counted once they reached a sub-confluence of 80%. At each passage cell were re-plated at 
the initial density and culture were performed until passage 5. Three samples for each 
condition were used. The following formula was applied: 
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N is the harvested cell number and Ns is the initial plated cell number. Cumulative 
population doublings (CPD) index for each passage was obtained by adding the PD of each 
passage to the PD of the previous passages. 
 
Clonogenicity, senescence and cell death 
In order to evaluate colony forming ability, hDPSCs cultured in HS-medium and in FCS-
medium were seeded at clonal density (1,6 cells/cm
2
) in 6-well plates and cultured for 10 
days. Six samples for each culture condition were fixed in 4% paraformaldehyde in 
phosphate buffered saline (PBS) and stained with Toluidine blue. Counting was performed 
considering only colonies consisting of more than 10 cells. In order to evaluate the 
presence of senescent cells in hDPSCs maintained in HS-medium and in FCS-medium, 
cells at 5
th passage were seeded in 12-well plates and cultured until reaching the 
confluence. Samples were then processed by a senescence β-Galactosidase staining kit 
(Cell Signaling), according to manufacturer’s instructions. Three samples for each culture 
condition were analyzed and percentage of senescent cells was calculated. 
The presence of apoptotic cells in hDPSCs cultures was analyzed by detection of the 
cleaved form of poli(ADP-ribose) polymerase (PARP). Whole cell lysates of hDPSCs 
cultured in HS-medium and in FCS-medium at passages 1, 3 and 5 were processed for 
Western blot analysis and PARP was detected by an anti-PARP specific Ab (Santa Cruz). 
FACS analysis. Isolated hDPSCs cultured for 5 passages in FCS-medium and HS-medium 
were assayed for the expression of Stro-1, c-Kit and CD34 surface antigens. Indirect 
staining was performed using mouse anti-STRO-1 IgM, rabbit anti-c-Kit IgG (Santa Cruz) 
and mouse anti-CD34 IgG (Millipore), followed by goat anti-mouse-IgG-Alexa488, goat 
anti-rabbit-IgG-Alexa488; 
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and goat anti-mouse-IgM-Alexa488 (Invitrogen). Non-specific fluorescence was assessed 
by using normal mouse IgG or IgM followed by the secondary antibody as described 
above. Samples were analyzed using a 16-parameters CyFlow ML flow cytometer (Partec 
GmbH), equipped with a 488-nm blue solid-state, a 635-nm red diode laser, a UV mercury 
lamp HBO, a 532 nm green solid state laser, a 405 nm violet laser, and a CCD camera. 
Data were acquired in list mode by using FloMax (Partec GmbH) software, and then 
analyzed by FlowJo 9.4.11(Treestar Inc.) under MacOS 10. A minimum of 20000 cells per 
sample were acquired. 
 
In vitro multilineage differentiation  
Human DPSCs cultured in HS-medium and FCS-medium were tested for their ability to 
differentiate towards neurogenic, adipogenic and myogenic lineages. Three samples of 
each culture condition were used for each differentiation experiment.  
Myogenic differentiation experiments were carried out according to Laino et al. (Laino G 
et al, 2006). In order to investigate the capability of hDPSCs to participate in myotubes 
formation, cells were seeded in direct co-culture with C2C12 mouse myoblast cell line. 
Human DPSCs and C2C12 cells were seeded in a 10:1 ratio in DMEM High Glucose, 
supplemented with 10% FBS or HS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, until confluence was reached. Upon confluence, growth medium was 
replaced with DMEM High Glucose supplemented with 1% FBS or HS and 10 nM insulin. 
Cells were maintained in co-culture for 2 weeks. Double immunofluorescence staining, by 
using an anti-human mitochondrial protein ab (anti-hMit; Millipore) and an anti-Myosin ab 
(Sigma Aldrich), was performed in order to verify the formation of myotubes with the 
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direct contribution of hDPSCs. Neurogenic and adipogenic differentiation were performed 
as described by Zhang et al. (Zhang W et al, 2006).  
Neurogenic differentiation: cells were seeded on 6-well plates at 20000 cells/cm
2
. After 
confluency was reached, cells were pre-induced with FCS-medium or HS-medium 
supplemented with 1 mM β-mercaptoethanol. After 24 h, the cells were washed and 
differentiated in serum free α-MEM containing 10 mM β-mercaptoethanol, 2% dimethyl 
sulfoxide and 200 µM butylated hydroxyanisole until neuronal morphology was detectable. 
Neuronal differentiation was assayed for expression of β3-Tubulin by immunofluorescence 
experiments using specific ab (Cell Signaling). 
Adipogenic differentiation: cells were seeded on 24-well plates at 20000 cells/cm
2
. 
Subconfluent cultures were incubated in the adipogenic medium (FCS-medium or HS-
medium containing 0,5 mM isobutyl-methylxanthine, 1 µM dexamethasone, 10 µM 
insulin, 200 µM indomethacin, 50 mg/ml gentamicin) for 3 weeks. Medium was changed 
every 3 days. Afterwards, cells were stained with oil red O stain and counterstained with 
Harris haematoxylin. 
 
In vitro osteogenic differentiation  
In order to obtain osteogenic differentiation on 2D surface, STRO-1
+
 hDPSCs were seeded 
at approximately 3000 cells/cm
2
 on culture dishes in two different osteogenic media 
(culture medium supplemented with 100 µM 2P-ascorbic acid, 100 nM dexamethasone, 10 
mM β-glycerophosphate) containing 5% FCS (FCS-osteogenic medium) and 5% HS (HS-
osteogenic medium), respectively. In particular hDPSCs cultured in HS-medium were 
differentiated in HS-osteogenic medium while cells cultured in FCS-medium were 
differentiated in FCS-osteogenic medium. The media were changed twice a week. 
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Collagen sponges (Condress, ABIOGEN PHARMA S.p.A.) were used as 3D scaffold in 
this study, for the subsequent in vivo implantation. Cells were seeded on collagen sponge 
samples (13 mm diameter; 1,5 mm height), into a 12 multi-well plate, in an adequate 
volume of culture medium to obtain a starting density of about 1  106 cells per sponge. 
After 8 hours from cell seeding, 2 ml of the two osteogenic media were added to each 
sample. Human DPSCs/collagen constructs were pre-differentiated for 10 days before in 
vivo implantation as described above in this section.  
 
Surgery and implantation procedure 
The in vivo implantation has been realized in 14 weeks old Sprague-Dawley male rats and 
surgical procedure was performed as described above in this section. 
In order to compare the bone forming ability of hDPSCs on collagen scaffolds in both pre-
differentiation conditions, a critical size bone defect was generated by a full-thickness 
dissection of both the internal and external tables of compact bone constituting the parietal 
skeletal segment. The stem cell-scaffold complexes were then implanted into the critical 
size parietal defect up to 6 weeks. One scaffold 5  8  1,5 mm size was implanted into 
each cranial defect and adapted to fill the whole defect area; each animal received two 
constructs: on the left parietal bone the construct pre-differentiated with FCS-osteogenic 
medium; on the right parietal bone the construct treated with HS-osteogenic medium. 
Control group received collagen scaffold alone. Six weeks after the surgical implantation 
the rats were sacrificed and the calvarias were rapidly explanted and fixed in 4% 
paraformaldehyde in PBS for 3 h. A total of 10 animals were used in this study (controls 
n= 4; 
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treated n= 6). All animal procedures were performed according to the guidelines approved 
by the Committee of Use and Care of Laboratory Animals of the University of Modena e 
Reggio Emilia. 
 
Histology, histochemistry and morphometry 
Some samples of hDPSCs differentiated in vitro were fixed in 4% paraformaldehyde in 
phosphate buffered saline (PBS) at pH 7.4 for 20 minutes and were processed for 
subsequent steps. For Alizarin red staining fixed cells were incubated for 5 minutes at 
room temperature in a solution containing 0,1% alizarin red and 1% ammonium hydroxide. 
Other samples were fixed in methanol-acetone 3:7 for 10 minutes at - 20°C, in order to 
perform the alkaline phosphatase assay. For this enzymatic assay fixed cells were 
processed by using Leukocyte Alkaline Phosphatase Kit (Sigma Aldrich), following the 
manufacturer’s instructions. Images were collected by a CCD color camera equipped with 
a 90 mm macro photograph objective. Densitometry was performed on culture plates from 
three independent experiments by NIS software (Nikon). An equal area (ROI) was selected 
around the plate surface and the mean of gray levels (in a 0–256 scale) was calculated. 
Data were then normalized to values of background and expressed as mean ± SD. Fixed 
samples of explanted calvarias were immersed in 0,5 M EDTA pH 8.3 until the complete 
decalcification and then rinsed in PBS, dehydrated with graded ethanol, diaphanized and 
embedded in paraffin. Transversal serial sections (10 µm thick) of the parietal bones 
containing the implants, were cut. Routine H & E staining was performed in order to 
analyze morphological details. Images of histological samples were obtained with a Nikon 
Labophot-2 optical microscope equipped with a DS-5Mc CCD color camera. 
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Morphometry on regenerating bone areas was performed by NIS software (Nikon). Implant 
area and new-formed bone area were measured in 5 transversal sections of implanted 
parietal bone for each animal. Percentage of new-formed bone was calculated in 
comparison to the total area of implant. Vasa, identified by morphological criteria and by 
labeling with anti-von Willebrand factor ab, were counted in the area of not yet reabsorbed 
scaffold and in the area of new-formed bone for each animal and for each implant type. 
Data were normalized to areas of not yet reabsorbed scaffold and of new-formed bone 
respectively and were presented as mean ± SD of each experimental group (controls n = 4; 
treated n =6).  
 
Confocal microscopy 
Fixed monolayer cells were permeabilized with 0,1% Triton X-100 in PBS for 5 minutes; 
samples were then blocked with 3% BSA in PBS for 30 minutes at room temperature and 
then incubated with the primary antibodies diluted 1:50 [rabbit anti-osteocalcin (OCN), 
mouse anti-osteopontin (OPN), rabbit anti-osterix (Osx), rabbit anti-Runx2, mouse anti-
hMit, rabbit-anti myosin, mouse anti-β3-Tubulin] in PBS containing 3% BSA, for 1 hour 
at room temperature. After washing in PBS containing 3% BSA, the samples were 
incubated for 1 hour at room temperature with the secondary antibodies diluted 1:200 in 
PBS containing 3% BSA (goat anti-rabbit FITC, sheep anti-mouse FITC, donkey anti-
rabbit Cy3). After washing in PBS samples were stained with 1 µg/ml DAPI in PBS for 1 
minute, and then mounted with anti-fading medium (0,21 M DABCO and 90% glycerol in 
0,02 M Tris, pH 8.0). 
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Histological sections were processed as described above. Primary antibodies (mouse anti-
hMit, rabbit anti-OCN, Millipore; rabbit anti-von Willebrand factor, Sigma Aldrich) were 
diluted 1:80 in PBS containing  3% BSA for 1 hour at room temperature. Secondary 
antibodies were diluted 1:200 in PBS containing 3% BSA (goat anti-mouse alexa488, goat 
anti- rabbit alexa546, Life Technologies). Negative controls were samples not incubated 
with the primary antibody. The multi-labeling immunofluorescence experiments were 
carried out avoiding cross-reactions between primary and secondary antibodies. 
Immunohistochemistry with ant-hMit revealed by a HRP-labeled anti-mouse secondary Ab 
(Pierce) was performed in order to confirm specificity of the labeling. HRP was revealed 
by a DAB based kit (Sigma Aldrich). Control without primary Ab was also performed. 
Fluorescent samples were observed by a Nikon A1 confocal laser scanning microscope as 
described below. For detection, the 
samples were sequentially excited with the respective laser wavelength: 405 nm lines of a 
diode laser for DAPI; 488 nm lines of the argon laser for FITC or alexa488; 543 nm line of 
a HeNe laser for Cy3 or alexa546. The excitation and the detection of the samples were 
carried out in sequential mode to avoid overlapping of the two signals. Optical sections 
were obtained at increments of 0,3 µm in the z-axis and were digitized with a scanning 
mode format of 1024 1024 pixels and 4096 gray levels. 
The confocal serial sections were processed with ImageJ software to obtain three-
dimensional projections and image rendering was performed by Adobe Photoshop 
Software. 
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Western Blot 
Whole cell lysates were obtained at different times of differentiation by using an hypotonic 
buffer (30 mM Tris-Cl, pH 7.8, containing 1% Nonidet P40, 1 mM EDTA, 1 mM EGTA, 1 
mM Na3VO4, and freshly added Sigma-Aldrich Protease Inhibitor Cocktail). Lysates were 
cleared by centrifugation and the total lysate was immediately boiled in SDS sample 
buffer. The protocols of the Western blot were performed as described by Sambrook et al. 
(Sambrook J et al, 1989). 
Sixty µg of protein extract, quantified by a Bradford Protein Assay (Biorad), underwent 
SDS-polyacrylamide gel electrophoresis and were transferred to PVDF membranes. The 
following antibodies were used: rabbit anti-osteocalcin antibody diluted 1:500; mouse anti-
collagen type I (Millipore), rabbit anti-PARP (Santa Cruz) diluted 1:1000; peroxidase-
labeled anti-rabbit and anti-mouse secondary antibodies diluted 1:3000 (Pierce Antibodies, 
Thermo Scientific). Antibody dilution was performed in TBS-T, pH 7.6, containing 2% 
BSA and 3% free fatty milk. The membranes were visualized by using ECL (enhanced 
chemioluminescence, Amersham). Anti-actin antibody was used as control of protein 
loading. Densitometry of cleaved PARP bands was performed by NIS software (Nikon). 
An equal area was selected inside each band and the mean of gray levels (in a 0–256 scale) 
was calculated. Data were then normalized to values of background and of control actin 
band. 
 
Statistical analysis 
All experiments were performed in triplicate. Quantitative or semi-quantitative data were 
expressed as mean ± standard deviation (SD). Differences between two experimental 
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points or between experiments were evaluated by paired Student’s t-test. ANOVA test 
followed by Bonferroni post-test was used to analyze differences between three or more 
experimental points. In all analyses, values of p<0,01 were considered a significant 
statistical difference, while values of p<0,001 were considered a strong significant 
statistical difference.  
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1.3 Skeletal muscle regeneration by human DPSCs and AFSCs 
Cell culture and sorting 
Human dental pulp and amniotic fluid stem cells were isolated and immuno-selected as 
described in Materials and methods section, paragraph 1.1.  
Both the cell populations, STRO-1
+
 hDPSCs and c-kit
+
 hAFSCs , were expanded in culture 
medium containing α-MEM plus 20% Foetal Calf Serum (FCS), 2mM L-glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin (Sigma Aldrich), at 37° C and 5% CO2. 
 
Myogenic differentiation in vitro 
After cell expansion, in order to evaluate the myogenic potential of STRO-1
+ 
hDPSCs and 
c-kit
+ 
hAFSCs, these cells underwent two different differentiation protocols.  
The first protocol consisted in a direct co-culture of hDPSCs/hAFSCs with C2C12 mouse 
myoblast cell line: human stem cells and mouse myoblasts were seeded on cover-slides 
into 6-well plates, at 10:1 cell seeding ratio, and maintained in an expansion medium 
containing DMEM High Glucose (DMEM-HG) plus 10% FCS, 2mM L-glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin, until confluence was reached. After reaching 
confluence, the expansion medium was replaced by fusion medium, containing DMEM-
HG plus 1% FCS, 2mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 
10nM insulin. Co-cultures were held in fusion medium for 14 days. 
The second protocol, on the other hand, involved the myogenic differentiation of hDPSCs 
and hAFSCs by means of the DNA demethylating agent, 5-Aza-2’-deoxycytidine (5-Aza, 
Sigma Aldrich). 
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Cells were seeded on cover-slides into 6-well plates, without direct co-culture, at a cell 
density of 4000 cells/cm
2
 in expansion medium (DMEM-HG plus 10% FCS, 2mM L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin) upon reaching confluence, then 
the medium was replaced with DMEM Low Glucose (DMEM-LG), plus 10% horse serum, 
0,5% chicken serum, 2mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 
additioned with 10µM 5-Aza for 24 hours. Subsequently, cells were rinsed twice in 
Phosphate Buffer Solution (PBS) and kept in myogenic medium containing DMEM-LG, 
plus 5% horse serum, 0,5% chicken serum, 2mM L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin, and 10nM insulin, for 24 hours. The day after, horse serum 
concentration in myogenic medium was reduced to 2%; half of the hDPSCs and hAFSCs 
was differentiated under these conditions, the other half underwent the same treatment, 
with the addition of conditioned fusion medium from differentiated C2C12 cells.  
 
In vivo transplantation of hDPSCs and hAFSCs in SCID/mdx mice 
In order to evaluate whether the hDPSCs and hAFSCs are capable to regenerate injured 
skeletal muscle and restore dystrophin expression, both human stem cell lines formerly 
demethylated by means of 10µM 5-Aza and pre-differentiated in vitro for 2 weeks in 
myogenic medium, with and without the addition of conditioned fusion medium from 
differentiated C2C12 cells, were transplanted into an animal model of Duchenne Muscular 
Dystrophy, the SCID/mdx mouse.  
Briefly, 5   105 pre-differentiated hDPSCs and hAFSCs, resuspended in 30µl of PBS, 
were injected into gastrocnemia muscles of male SCID/mdx mice, with age ranging 
between 8 and 10 weeks. Each animal received two injections: on the left gastrocnemius 
muscle, the cells pre-differentiated after demethylating treatment; on the right 
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gastrocnemius muscle, the cells pre-differentiated after demethylating treatment, with the 
addition of conditioned medium.  Non-injected and PBS-injected muscles were taken as 
controls. The animals were euthanized at 7, 14, and 28 days after cell transplantation. The 
gastrocnemia muscles were rapidly harvested, and snap frozen in liquid nitrogen. 
Subsequently, transversal serial sections (8µm thick) of frozen muscles were cut by means 
of a H525 MICROM Cryostat, collected on Super Frost Plus slides (Thermo Scientific) 
and then stored at - 80°C.  A total of 10 animals were used in this study (controls n=4; 
treated n = 6).  
Animal procedures were performed in compliance to the guidelines approved by the 
Institutional Animal Care and Use Committee (IACUC) of the University of Pittsburgh, 
Pittsburgh, PA, USA. 
 
Immunofluorescence microscopy and histology 
Fixed monolayer cells differentiated in vitro on cover-slides were permeabilized with 0,1% 
Triton X-100 in PBS for 5 minutes; samples were then blocked with 3% BSA in PBS for 
30 minutes at room temperature. Mouse anti-human nuclei (Millipore), mouse anti-
myogenin,  rabbit anti-myosin heavy chain (MyHC), rabbit anti-desmin (all from Sigma 
Aldrich), diluted 1:50 in PBS containing 3% BSA for 1 hour at room temperature were 
used as primary antibodies (abs). Secondary abs were diluted 1:200 in PBS containing 3% 
BSA for 1 hour at room temperature (goat anti-mouse Alexa488, donkey anti-rabbit 
Alexa594; Invitrogen), after washing in PBS cells were counterstained with 1 µg/mL DAPI 
in PBS for 3 minutes, and then mounted with anti-fading medium (0.21 M DABCO and 
90% glycerol in 0.02 M Tris, pH8.0). Negative controls consisted of samples not incubated 
with the primary antibody. 
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Histological unfixed sections from frozen muscle were processed as described above.  
Mouse anti-human mitochondrial protein (1:80, Millipore), rabbit anti-dystrophin (1:500, 
courtesy of Dr. Bing Wang, University of Pittsburgh, PA) and rabbit anti-human von 
Willebrand factor (1:100, Millipore), were used as primary abs. Secondary abs, diluted 
1:200, were donkey anti-mouse Alexa488, donkey anti-rabbit Alexa594, donkey anti-
mouse Alexa594 and goat anti-rabbit Alexa488 (Invitrogen). Negative controls were 
samples not incubated with the primary antibody. The multi-labeling immunofluorescence 
experiments were carried out avoiding cross-reactions between primary and secondary 
antibodies. 
Immunofluorescence analysis was performed on a Nikon Eclipse E800 microscope 
(Nikon), with the use of Northern Eclipse imaging software (EMPIX Imaging). The image 
rendering was performed by Adobe Photoshop software.  
Routine H & E staining was performed in order to analyze the morphological details. 
Moreover, trichrome staining was performed to detect the collagen content of the muscles. 
Slides were processed as detailed in the manufacturer’s protocol (Masson’s Trichrome 
stain kit; IMEB, Inc.). Images of histological samples were obtained with a Nikon Eclipse 
E800 microscope (Nikon).  
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1.1 In vivo implantation of stem cells-scaffold constructs 
In order to evaluate the capability of hDPSC-scaffold and hAFSC-scaffold complexes to 
repair critical size bone defects in vivo, these human stem cells were pre-differentiated 
towards osteogenic lineage in vitro, following the seeding on three different types of 
scaffolds: silk fibroin, equine collagen, and poly-D,L-lactic acid (PDLLA). After pre-
differentiation of hDPSC- and hAFSC-scaffold constructs in osteogenic medium,  a 
critical-size bone defect was obtained through a full-thickness resection of both the internal 
and external tables of almost 95% of the parietal bone of immunocompromised rats; then 
the constructs were implanted into the critical size parietal defect and 4 weeks later the rats 
were euthanized and the calvaria were explanted and processed for further evaluation by 
radiological, histological and confocal analysis. 
 
 Scaffold characterization: morphology, water content, porosity and mechanical 
properties 
Scaffold morphology was evaluated by FE-SEM on dry samples. The micrographs of 
fibroin sponges are shown in Figure 8. Their morphologies are characterized by a high and 
interconnected porosity but with a different pore diameter range, from 10 to 250 µm; 
moreover, pores are randomly distributed. 
The open porosity as measured by the hexane displacement test was evaluated around 85% 
± 5%, while a water content equal 89% by wt. was measured for fibroin sponges. The data 
are very close so indicating that most of the water filled the pores and only a negligible 
amount swelled the 
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solid polymer. Compressive elastic properties of the sponges reflected the effect of 
material porosity, the absorbed water within the pores, but also the plasticization of the 
polymer. 
In the wet state, however, fibroin sponges retained their mechanical consistence, with a 
measured compressive modulus of 25,69 ±1,61 kPa. 
 
 
 
 
 Radiological analysis 
First, the bone healing process at the cranial defects was evaluated by radiograph 30 days 
after surgery. Figure 9 shows that the scaffold alone is able to slightly repair the area 
removed by the drill. In particular, the fibroin scaffold healed the bone defect mainly in 
lateral areas, while no bone repair was observed in the central area of the implant.  
Figure 8. Scanning electron microscopy images of salt-leached 
fibroin scaffold. 
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Broadly, the presence of stem cells into collagen and fibroin scaffolds enhances the 
radiopacity of the bone defect area that appears similar to the intact bone (Figure 9).  
With regard to the implant with PDLLA scaffold either alone or plus the cell, the 
radiological analysis did not show any significant bone regeneration (not shown).  
 
 Histological analysis  
In order to analyze the bone reconstruction process through histological analysis, serial 
sections of the parietal bones containing the implants were stained by H&E labeling. The 
samples were then observed by white field and polarized light microscopy. The presence of 
vessels in the scaffold area shows that all implanted constructs have been successfully 
vascularised (Figure 10D, F, G, K, L). 
The untreated critical-size bone defects, after 30 days, are filled by connective tissue only 
and lack a significant amount of bone tissue in comparison to the intact parietal bone 
(Figure 10A, B). 
Radiographic data for fibroin are confirmed by histological analysis (Figure 10), since the 
implantation with the scaffold alone causes the formation of small mineralized spots spread 
Figure 9. Radiological analysis of rat calvaria dissected 30 days after surgery. Images are representative of the bone 
healing in the cranial defects of fibroin scaffolds alone and fibroin scaffold seeded with human dental pulp stem 
cells (hDPSCs) or human amniotic fluid stem cells (hAFSCs). 
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throughout the defect area (Figure 10C–E). This can be an adequate starting step for bone 
regeneration by stem cells. As a matter of fact, the samples containing hDPSCs and 
hAFSCs even more (Figure 10F, K) show a complete reconstruction of the internal table of 
parietal bone and an extensive but incomplete regeneration of the external one. Moreover, 
areas of spongy bone were present between the two tables of compact bone (Figure 10F, G, 
K, L). Polarized light microscopy analysis indicates that newly formed bone presents some 
areas with lamellar organization compared with pre-existing bone characterized by a clear 
lamellar structure (Figure 10H, M). Magnification images highlight area of active bone 
deposition, as evidenced by the presence of preosteocyte cells partially included in forming 
lacunae (Figure 10J) and fibroin remnant islands wrapped by the new mineralized tissue 
(Figure 10G, N, O). This means that a progressive resorption of fibroin leaded to 
ossification process. Fibroin colonized with hAFSCs seems to have a greater regenerative 
potential compared to hDPSC/fibroin complex, indeed it forms bone also in scaffold areas 
distant from dura mater (Figure 10F, K). The in vivo data showed that fibroin scaffolds 
provided hAFSCs and hDPSCs with an optimal microenvironment for their osteogenic 
differentiation and bone formation. 
Radiographic data from the implant with collagen scaffold, with and without the cells, 
were confirmed by the histological analysis, in fact it did not produce any relevant bone 
reconstruction, as well as the implant with PDLLA scaffold did, either alone and with cells 
(data not shown).   
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Figure 10. Comparative histologic analysis of the cranial defect reconstruction by fibroin constructs at 30 days post-
surgery. Images show transversal sections carried out through the central area of the implants. H&E staining of 
parietal bone (A) and cranial defect: unfilled (B); filled with fibroin (C and magnification D); filled with fibroin + hDPSCs 
(F and magnifications G, I, J); filled with fibroin + hAFSCs (K and magnifications L, N, O). (E), (H), and (M) are the same 
field of (D), (G), and (L) observed by polarized microscopy. Black arrowheads indicate vasa; yellow arrowheads 
indicate fibroin remnants.  
79 
 
 Confocal analysis 
To check whether the cells inside the new bone were still from human origin and not from 
the host, immunofluorescence experiments with anti-human mitochondria antibody were 
carried out. This antibody recognizes only mitochondrial protein from human origin. In 
control samples (fibroin alone, Figure 11A, B) only DAPI staining (red signal) occurs, 
while human mitochondria (green signal) are not detectable.  
 
 
 
 
 
The autofluorescence phenomenon of fibroin is also evident. Images of stem cell/scaffold 
implants demonstrate that most of the cells are clearly labeled by anti-human mitochondria 
antibody (Figure 11C–G), indicating the survival of donor cells in vivo. In particular, 
Figure 11C, D, F, and G shows that human cells surround the bone tissue in growth. 
Furthermore, in Figure 11F, it is evident that the new-formed bone tissue wraps modified  
fibroin islands. 
Figure 11. Confocal images of implants obtained 4 weeks after surgery. Double 
immunofluorescence staining with DAPI (red) and anti-human mitochondria protein 
antibody (green), the signals were superimposed to pseudo-phase contrast images. (A, B) 
Fibroin scaffold: no human stem cells were detectable within the fibroin scaffold alone. 
The square indicates the image area magnified on the right. Asterisks indicate bone tissue. 
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Moreover, Figure 11D, E, and G highlights that human cells are enclosed within bone 
lacunae. These data confirm the central role of human stem cells in bone regeneration after 
cell/scaffold implant in rat model of large cranial defects. 
 
 
 
Figure 11. Confocal images of implants obtained 4 weeks after surgery. Double 
immunofluorescence staining was performed with DAPI (red) and anti-human 
mitochondria protein antibody (green). (C–E) fibroin colonized with hDPSCs; (F–G) fibroin 
colonized with hAFSCs. Squares indicate the image areas magnified on the right. Asterisks 
indicate bone tissue. 
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1.2 Human serum for osteogenic differentiation of human DPSCs 
 
 Cell Proliferation 
To evaluate the influence of HS or FCS on the growth of hDPSCs during routine cell 
culture, proliferation rate was evaluated by using 6-CFDA staining to detect viable cells in 
adherent culture at different times until confluence was reached. Human DPSCs were then 
grown in culture media without serum, or containing respectively 10% FCS and 10% HS, 
and cell counting was performed for up to 7 days (Figure 12A).  
 
 
 
 
Human DPSCs cultured in serum-free medium do not show any significant proliferation 
rate, indicating a stationary trend. Cells cultured with HS show, at the beginning, a slightly 
lower proliferation rate compared to hDPSCs growing in FCS-medium. From day 4 
Figure 12. A: CFDA vital staining of hDPSCs cultured for 1, 4 and 7 days, in serum-
free medium, HS-medium and FCS-medium. Green signal indicates viable cells. Bar: 
100 µm. 
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onward the proliferation rate of cells in HS-medium slightly exceeds, in significant 
manner, the one of hDPSCs growing in FCS-medium (Figure 12B). Furthermore the 
population doubling time of HS cultures is lower than FCS cultures (HS: 35,0 ± 2,31 
hours; FCS: 40,3 ± 1,50 hours; p < 0,01). Cumulative population doubling analysis shows 
that HS culture proliferates more speedily, overtaking FCS culture by 13% at each passage 
(Figure 12C). Human DPSCs cultured in HS-medium or in FCS-medium for 5 passages 
were seeded at clonal density and cultured in 6-well culture plates for 10 days, in order to 
verify any differences in clonogenic ability. No significant differences were observed in 
the number of colonies formed by hDPSCs growing in the two culture conditions (HS 17,3 
± 4,8 colonies; FCS 18,7 ± 4,0 colonies). 
 
 
 
 
 
 Senescence and apoptosis 
Cell senescence was evaluated by detection of β-galactosidase activity in confluent culture 
of hDPSCs grown for 5 passages in HS-medium or in FCS-medium. Very low levels of β-
Figure 12. B: Proliferation rate of hDPSCs cultured for one week. Values are mean reported in a Log scale, n = 3; * 
indicates values of paired t-test HS vs. FCS (**p<0,01, ***p<0,001). C: Cumulative population doubling (CPD) of 
hDPSCs cultured for a total of 5 passages. At each passage cells cultured in HS-medium show a CPD significantly 
higher than FCS-medium cultured cells (n = 3; ***p<0,001). 
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galactosidase activity were detected in both culture conditions (Figure 12D arrowheads). In 
particular no significant differences were observed in the percentage of senescent cells 
detected by microscopic observation in the two culture conditions (FCS 0,044 ± 0,007%; 
HS 0.039 ± 0.004%; n= 3). 
Western blot analysis of PARP carried out in hDPSCs at passages 1, 3 and 5, shows an 
equivalent amount of uncleaved PARP (116 kDa) in both culture conditions. On the other 
hand positive control (etoposide treated HL60 cell line), shows a clear band in 
correspondence of cleaved PARP form (89 kDa; Figure 12E) that is not appreciable in 
hDPSCs. Densitometry performed on the cleaved PARP bands did not show significant 
differences between HS and FCS cultured DPSCs. 
These data indicate that HS-medium does not induce premature senescence and does not 
affect the survival of hDPSCs. 
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 Surface antigens expression and in vitro multi-lineage differentiation 
In order to verify whether HS affects the stemness of hDPSCs during in vitro culture, 
surface antigens expression and multi-lineage differentiation ability were evaluated in 
hDPSCs cultured in HS-medium and in FCS-medium. Stro-1, c-Kit, and CD34 are surface 
Figure 12. D shows b-galactosidase activity staining in confluent culture of 
hDPSCs grown for 5 passages in FCS-medium or in HS-medium as indicated. 
Arrowheads indicate cells positive to bgalactosidase activity staining. Bar 10 µm. 
E: western blot analysis of PARP in hDPSCs cultured in FCS-medium and in HS-
medium at passages 1, 3 and 5. HL60, treated with etoposide, were loaded as 
positive control of the presence of cleaved PARP (cPARP). Actin bands were 
presented as control of the protein loading. Densitometry of cPARP bands was 
shown on the bottom of western blot images. 
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antigens typical of hDPSCs (49 Graziano et al, 2008). FACS analysis performed in 
hDPSCs in both culture conditions after 5 passages, demonstrates that hDPSCs maintain 
the expression of the above mentioned antigens. Moreover, the fluorescence intensity of c-
Kit labeling appears higher in HS-cultures, indicating that the whole population expresses 
this antigen at a dim level. Stro-1 and CD34 antigens appear equally expressed (Figure 
13A).  
 
              
 
Figure 13. hDPSCs 
surface antigens 
expression. A: 
Cytofluorimetric 
analysis of Stro-1, c-
Kit and CD34 
expression in 
hDPSCs cultured in 
FCS-medium and in 
HS-medium. Dot 
plots reporting SSC 
vs fluorescence are 
shown. In the 
histograms, the net 
fluorescence value 
was calculated by 
linearizing the 
fluorescence value 
from the 
logarithmic scale 
and subtracting the 
linearized value of 
the unstained 
sample to the 
linearized value of 
the stained one. 
Data represent the 
mean ± SD of three 
different 
experiments. * 
indicates values of 
paired t-test HS vs. 
FCS (*p<0.05). 
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Human DPSCs cultured in both media were differentiated towards myogenic, adipogenic, 
neurogenic and osteogenic lineages as described in materials and methods. 
The ability of hDPSCs to differentiate towards myogenic lineage was verified by co-
culture with C2C12 mouse myoblasts. After 14 days of co-culture myotubes formation was 
observed both in HS co-cultures and in FCS co-cultures. Myotubes appear multinucleated 
indicating that cell fusion occurs. Labeling by anti-human mitochondria antibody (anti-
hMit) demonstrates that hDPSCs are involved in myotubes generation. Double staining 
with anti-hMit and anti-myosin antibodies indicates that in both culture conditions mature 
myotubes were formed with the contribution of hDPSCs. Myotubes not labeled by anti-
hMit antibody and therefore formed only by C2C12 cells were also present (Figure 13B). 
The percentage of myotubes formed with the contribution of hDPSCs respect to the total 
myotubes, was similar in both culture conditions (FCS 42,7 ± 6,4%; HS 46,3 ± 7,2%; n 
=3).  
Human DPSCs cultured in adipogenic medium supplemented with HS start to form 
intracellular lipidic drops after three days of differentiating culture while cells 
differentiating in FCS adipogenic medium show the first intracellular lipidic drops at day 
7. After two weeks of differentiation, hDPSCs in both conditions, show a similar 
morphology characterized by numerous lipidic drops accumulated in the cytoplasm and 
clearly stained by oil red (Figure 13B). The percentage of oil Red positive cells did not 
show significant differences between the two culture conditions (FCS 73,7 ± 8,1%; HS 
75,7 ± 9,0%; n= 3). 
Neurogenic differentiation starts with an initial cell detachment from culture plates 
probably induced by β-mercaptoethanol. 
87 
 
Remaining cells progressively assume neuronal morphology with multiple cellular 
processes and a defined cell body. Immunostaining with anti-β3-Tubulin after 20 days of 
culture shows the presence of neurotubules in hDPSCs pre-differentiated in FCS-medium 
as well as in HS-medium (Figure 13B). No particular differences, in the percentage of β3-
Tubulin positive cells, were observed between the two experimental groups (FCS 64,3 ± 
7,2%; HS 62,0 ± 7,6%; n= 3). 
 
 
 
 
Figure 13. hDPSCs multi-lineage differentiation in vitro. B: In the first line are 
shown double immunofluorescence images of hDPSCs/C2C12 co-culture 
stained by anti-hMit (green) and anti-myosin (red) Abs. DAPI staining is 
shown in blue. The second line shows oil red staining of hDPSCs 
differentiated for two weeks towards adipogenic lineage with HS or FCS 
supplemented medium. Cells were counterstained with Harris haematoxylin. 
Images, in third line represent anti-β3-Tubulin immunofluorescence labeling 
on hDPSCs differentiated in neurogenic media supplemented with FCS or HS. 
Bar 50 µm. 
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Human DPSCs differentiating towards the osteogenic lineage start to form nodular 
aggregates at day 8. At day 24, mineral deposits appear in the extracellular space and in 
nodular aggregates (data not shown). In cells, both the differentiation conditions induce an 
intense positivity to Alkaline phosphatase assay, which is extended to the whole culture 
plate. The in vitro deposition of mineralized extracellular matrix was analyzed by Alizarin 
red staining: differences were observed in Alizarin red staining, in favour of hDPSCs 
treated with HS (Figure 14A), which show a greater deposition of mineralized extracellular 
matrix than hDPSCs differentiated with FCS, as confirmed by densitometric analysis. 
A higher alkaline phosphatase activity was detected in HS-treated cells (Figure 14B). 
Controls of undifferentiated cells are negative for both the stainings (Figure 14A). 
 
 
 
 
 
The confocal analysis at day 24 shows the expression of osteocalcin, together with other 
specific markers of osteogenic commitment, such as osteopontin (OPN), osterix (Osx) and 
Runx2. Double immunofluorescence labeling was carried out to analyze simultaneously 
Figure 14. In vitro osteogenic differentiation of hDPSCs after 24 days of culture in osteogenic medium, 
supplemented with FCS or HS. A: Alkaline phosphatase assay (AP) and Alizarin Red staining; B: densitometric 
analysis of AP and Alizarin Red staining. Values are mean ± SD of gray levels (0–255 scale). HS n = 3; FCS n = 3; ** 
indicate values of paired t-test HS vs. FCS (p<0.01). 
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the localization of OPN and Runx2 in hDPSCs differentiated with FCS-medium or HS-
medium (Figure 14C). OPN appears localized in the cytoplasm perinuclear region, that 
normally contains the rough endoplasmic reticulum, while Runx2 is localized in the cell 
nucleus as expected. OCN shows a typical cytoplasmic localization, strongly expressed in 
both the differentiation conditions. Signal from OCN was also detected in extracelluar 
matrix where it appears as spot localized in mineralization areas. Similarly to Runx2, Osx 
shows the typical nucleoplasmic localization, as demonstrated by the overlapping with 
DAPI signal (Figure 14C). No differences were observed between the two differentiation 
conditions. To confirm the differentiation of hDPSCs towards osteoblast-like cells, in both 
osteogenic media, the presence of type I collagen (Coll-I) and of the specific marker 
osteocalcin (OCN), was analyzed by Western blot in whole cell lysates of differentiating 
hDPSCs: Coll-I and OCN were detected in both the differentiating conditions, and show an 
increase of expression during the differentiation (Figure 14D). 
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 Osteogenic differentiation in vivo 
In order to evaluate whether the use of different sera (FCS and HS) during pre-
differentiation of hDPSCs seeded in collagen scaffold, influences differently their ability to 
reconstruct critical size parietal bone defects, in vivo implants were performed as described 
in materials and methods section. After six weeks parietal bones containing the implants 
Figure 14. In vitro osteogenic differentiation of hDPSCs after 24 days of culture in osteogenic medium, supplemented 
with FCS or HS.  C: Confocal analysis of osteogenic differentiation of hDPSCs. Double immunofluorescence confocal 
images showing signals from anti-OPN (green) and anti-Runx2 (red); DAPI (blue) and anti-OCN (green); DAPI (blue) 
and anti-Osx (red). Bar: 50 µm. D: Western blot (WB) analysis of Coll-I and OCN expression in whole cell lysates of 
differentiated hDPSCs. Whole cell lysates were collected from three plates of human dental pulp stem cells for each 
differentiation protocol. Actin bands demonstrate that an equal amount of protein was loaded in each line. Undiff 
samples show hDPSCs cultured in FCS-medium alone. The same results were obtained in HS-medium culture (data 
not shown). 
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were histologically processed and observed by white field microscopy. Figure 15 shows 
representative photomicrographs of engineered bone grafts in vivo. The hDPSCs/collagen 
constructs realized in both pre-differentiation conditions exhibit an appreciable 
contribution to regeneration of the resected bone area (Figure 15A, 15D). Magnification 
images show the presence of vessels indicating a successful vascularization of the implants 
(Figure 15: B, C, E, F, arrowheads) and areas of active bone deposition and rearrangement, 
particularly detectable in samples pre-differentiated with osteogenic HS-medium, where 
osteoblast layer surrounds islets of new-formed bone (Figure 15E, 15F, star). 
Morphometric analysis was carried out in order to evaluate the amount of new-formed 
bone areas in animals implanted with collagen scaffold colonized with FCS or HS pre-
differentiated hDPSCs and in the control group implanted only with the collagen scaffold. 
The analysis revealed that animals implanted with scaffold colonized with hDPSCs pre-
differentiated in FCS and in HS differentiating medium show a bone regeneration 
significantly higher when compared to the control group (FCS vs C p<0.01; HS vs C 
p<0.001; Figure 15G). Moreover, by comparing HS implants with FCS implants emerges 
that the new-formed bone area is greater in HS implants respect to the FCS implants (HS 
vs FCS p<0.001; Figure 15G). The number of vasa in the scaffold not yet reabsorbed 
appears higher in HS pre-differentiated cells suggesting a better angiogenic potential. On 
the other hand the number of vasa in new-formed bone does not show significant 
differences among the three experimental groups indicating that the new-formed bone 
structure was not affected by the different pre-differentiation conditions (Figure 15H). 
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To verify whether cells inside the new-formed bone were still from human origin and not 
from the host, immunofluorescence labeling with anti-hMit antibody was performed. This 
antibody recognizes only mitochondrial protein from human origin: images of stem cell-
scaffold implants demonstrate that most of the cells are clearly stained by anti-human 
Figure 15. Comparative histological analysis (H&E staining) of the critical size cranial defect reconstruction by 
hDPSCs/collagen constructs 40 days post-surgery. Images show transversal sections carried out through the central 
area of the implants. A–C: cranial defect filled with hDPSCs/collagen pre-differentiated with FCS containing 
medium; D–F: cranial defect closed with hDPSCs/collagen pre-differentiated with HS containing medium; (dotted 
line delimitates the areas of bone resection; arrowheads indicate vasa; * indicate areas of active bone deposition). 
Bar: 100 µm. G: morphometric analysis of new-formed bone areas in controls (C), FCS and HS implants. Values are 
mean ± SD of the percentage of regenerated bone respect to the whole resected bone area. HS and FCS n = 6; C n 
= 4; white * inside the column indicate values of ANOVA test of HS and FCS vs. C (**p<0.01, ***p<0.001); black * 
indicate values of ANOVA test of HS vs. FCS (***p<0.001). Data, normalized to areas of the scaffold not yet 
reabsorbed and of new-formed bone areas respectively, were presented as mean ± SD (vasa number respect to 
the total implant area) of each experimental group (controls n = 4; treated n = 6). White * inside the column 
indicate values of ANOVA test of HS and FCS vs. C (***p<0.001); black * indicate values of ANOVA test of HS vs. FCS 
(*p<0.05). 
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mitochondria antibody (Figure 16 A–D) indicating survival of the donor cells in vivo, in 
both the pre-differentiation conditions.  
Interestingly, human DPSCs are included within bone lacunae indicating the direct 
contribution to the osteocytes population of new-formed bone. Double 
immunofluorescence analysis shows that human cells express OCN, which was detectable 
also in new-formed bone matrix (Figure 16 E–H). Moreover cells localized in the inner 
layer of vascular canals show a clear staining by anti-human mitochondria antibody, 
suggesting a direct contribution of hDPSCs to the angiogenetic process that gives rise to 
endothelial cells of new-formed vasa. As a matter of fact, double labelling by anti-hMit 
and anti-von Willebrand factor indicates that hDPSCs contribute to the constitution of the 
endothelium of vasa localized in the new-formed bone (Figure 16 I–L). 
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Figure 16. Confocal images of implants pre-differentiated in both the conditions. A–D: Double fluorescence signals 
from DAPI (blue) and anti-hMit Ab (green) superimposed to pseudo-phase contrast images (B, D). Arrowheads 
indicate cells entrapped in calcified bone matrix clearly stained by anti-human mitochondria antibody. E–H: triple 
fluorescence signals from DAPI (blue) and anti-hMit (green) and anti-OCN (red) Abs superimposed to pseudo-phase 
contrast images (F, H). Yellow arrowheads indicate osteocytes labelled by the two Abs; cyan arrowheads indicate 
OCN deposits in extracelluar bone matrix. I–L: triple fluorescence signals from DAPI (blue) and anti-hMit (green) 
and anti-von Willebrand factor (red) Abs superimposed to pseudo-phase contrast images (J, L). Arrowheads 
indicate vasa double stained by the two Abs. Bar: 10 µm. 
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1.3 Skeletal muscle regeneration by hDPSCs and hAFSCs 
 Myogenic differentiation in vitro 
In order to test their myogenic potential human AFSCs and DPSCs were induced towards 
the myogenic differentiation in vitro by means of two different protocols, based on a direct 
co-culture with C2C12 mouse myoblasts and on a DNA demethylating treatment with 5-
Aza-2’-deoxycytidine, respectively.  
 
  
 
The immunofluorescence analysis performed on hDPSCs and hAFSCs after 14 days of 
direct co- culture with C2C12 cells revealed the formation of new myotubes showing a 
positive staining with both anti-human nuclei and anti-myosin heavy chain (MyHC) abs, as 
shown in Figure 17. In particular, new-formed hybrid myotubes containing central nuclei 
either of human and mouse origin were observed, thus demonstrating a shared participation 
of human stem cells and mouse myoblasts to the formation of functional new myotubes. 
Immunofluorescent labeling was also carried out on hDPSCs and hAFSCs differentiated 
alone, after the DNA demethylation treatment with 5-Aza (Figure 18). Human AFSCs 
Figure 17. Immunofluorescence staining of direct co-cultures of hAFSCs and hDPSCs with C2C12 mouse myoblasts. 
New-formed myotubes are labeled with DAPI (blue), anti-human nuclei (green) and anti-myosin heavy chain (red) 
abs.  
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underwent the myogenic commitment, after 14 days of induction, as demonstrated by the 
positive staining for myogenin, one of the myogenic regulatory factors (MRFs), peculiar of 
the myogenesis process (Figure 18A).  
 
 
 
Figure 18. Immunofluorescence analysis of myogenic differentiation of hAFSCs and hDPSCs by 
means of demethylation treatment with 5-Aza. Immunofluorescence staining with DAPI (blue), 
anti-myogenin (green) and anti-myosin (red) abs. Myogenic differentiation was induced with (E-
H) and without (A-D) the addition of conditioned fusion media from differentiated C2C12.  
Human AFSCs and DPSCs underwent myogenic commitment after 14 (A,C, E, G) and 21 (B, D, F, H) 
days of induction, respectively. 
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Moreover, at the same time point, some hAFSCs also expressed myosin heavy chain, 
confirming a terminal myogenic commitment (Figure 18C). At 21 days of induction – one 
week later than hAFSCs -  hDPSCs expressed myogenin and myosin heavy chain as well 
(Figure 18B, 18D). 
Similar results were observed for both hDPSCs and hAFSCs differentiated after the 
demethylating treatment, with the addition of conditioned fusion media from differentiated 
C2C12 (Figure 18E-H).  
 
 Engraftment evaluation and muscle regeneration after in vivo transplantation 
Following the results observed in vitro the subsequent step of the study was to investigate 
the capability of human DPSCs and AFSCs pre-differentiated towards the myogenic 
lineage through the use of 5-Aza, with and without the addition of conditioned media from 
C2C12 cells, to regenerate the dystrophic skeletal muscle tissue of SCID/mdx mice, murine 
model of Duchenne muscular dystrophy. 
The animals treated with human DPSCs and AFSCs via intramuscular injection were 
sacrificed at different time points, and the explanted gastrocnemia muscles were processed 
for further analyses, with the aim to evaluate the successfulness of the treatment on 
different aspects. 
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Immunofluorescence analysis shows that as early as 7 days after injection, human DPSCs 
and AFSCs are present and appear to be histo-integrated within the host muscle, as 
demonstrated by the positive staining against human mitochondrial protein (Figure 19A, 
19C). Similar results were observed after both the pre-differentiating conditions (Figure 
19B, 19D).  
Furthermore, the double immunofluorescence staining, performed still 7 days after 
injection, with anti-human mitochondria (anti-hMit) and anti-von Willebrand factor (anti-
vWill) abs revealed that cells positively stained as endothelial cells within the vasa walls 
correspond to the human DPSCs and AFSCs specifically recognized by the anti-human 
Figure 19. Engraftment evaluation at 7 days. Immunofluorescence staining with DAPI (blue) and anti-
hMit ab (red) shows the presence of human DPSCs (A, B) and AFSCs (C, D) within the host dystrophic 
muscle, after the cell injection.  
A, C: muscular cryosections immunostained after injection of human stem cells pre-differentiated 
through demethylation treatment. 
B, D: muscular cryosections immunostained after injection of human stem cells pre-differentiated 
through demethylation treatment and addition of conditioned media from C2C12. 
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mitochondria ab (Figure 20A, 20C). Similar results were observed after both the pre-
differentiating conditions (Figure 20B, 20D).  
 
 
 
 
 
Moreover, two weeks after the cell injection, the immunofluorescent labelling showed the 
restored expression of dystrophin within the mouse dystrophic skeletal muscle fibers, as 
demonstrated by the positive staining against dystrophin. Interestingly, the fibers 
expressing dystrophin are also positively stained against the human mitochondrial protein 
(Figure 21A, 21C). Similar results were observed after both the pre-differentiating 
conditions (Figure 21B, 21D).  
Figure 20. Evaluation of angiogenesis promotion by human DPSCs and AFSCs 7 days after the 
injection. Immunofluorescence labeling with DAPI (blue), anti-vWill (green) and anti-hMit (red) abs. 
Green and red signals appear co-localized showing that human stem cells are present within the 
endothelium of new vasa. A, C: muscular cryosections immunostained after injection of human stem 
cells pre-differentiated through demethylation treatment. 
B, D: muscular cryosections immunostained after injection of human stem cells pre-differentiated 
through demethylation treatment and addition of conditioned media from C2C12. 
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Regenerated mouse muscle fibers positively labelled by anti-human mitochondria ab keep 
expressing dystrophin 4 weeks after cell injection (Figure 21E, 21G). Similar results were 
observed after both the pre-differentiating conditions (Figure 21F, 21H).  
 
 
 
Figure 21. Evaluation 
of muscle 
regeneration after 
cell injection. 
Immunofluorescence 
staining with DAPI 
(blue), anti-hMit 
(green) and anti-
dystrophin (red) abs 
shows the presence 
of human DPSCs (A, 
B) and AFSCs (C, D) 
within dystrophin 
positive muscle 
fibers, as early as 14 
days after the cell 
injection. The 
restored expression 
of dystrophin by 
muscle fibers 
containing human 
DPSCs and AFSCs can 
be observed still 28 
days after the 
treatment.  
A, C, E, G: muscular 
cryosections 
immunostained after 
injection of human 
stem cells pre-
differentiated 
through 
demethylation 
treatment. 
B, D, F, H: muscular 
cryosections 
immunostained after 
injection of human 
stem cells pre-
differentiated 
through 
demethylation 
treatment and 
addition of 
conditioned media 
from C2C12. 
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 Histological analysis 
To evaluate the evolution of fibrosis within the mouse dystrophic skeletal muscle after the 
treatment with human stem cells, serial sections of the gastrocnemia muscles injected with 
hDPSCs and hAFSCs were stained with H&E and Masson’s trichrome.  
Analysis of Masson’s trichrome staining in Figure 22 highlighted a reduction of fibrosis 
and necrosis processes within the muscle fibers treated with pre-differentiated hDPSCs and 
hAFSCs, compared to the controls (Figure 22A-C). At the same time, the histological 
analysis revealed that the muscles injected with human stem cells contain wide areas of 
muscle regeneration, as demonstrated by the high presence of centrinucleated muscle fibers 
(Figure 22D-F).  
 
 
 
 
  
Figure 22. Comparison of fibrosis and necrosis processes between controls (non-injected muscles) and muscles 
injected with human DPSCs and AFSCs. A, B, C: Masson’s trichrome highlights the reduction of fibrosis and necrosis 
within the muscles treated with human DPSCs (B) and AFSCs (C), while the controls (A) appear rich in fibrotic tissue 
(blue stained collagens). D, E, F: H&E shows an active muscle regeneration in progress within the muscles treated 
with human DPSCs (E) and AFSCs (F), as represented by a high number of centrinucleated muscle fibers (yellow 
arrowheads), whereas the controls (D) are characterized by a severe degeneration of the fibers. 
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Discussion 
1. Human DPSCs and AFSCs for bone tissue regeneration 
This section of the thesis investigated the future applications of human alternative stem 
cells in tissue engineering, including the application of human AFSC or DPSC/fibroin 
complexes to the repair of bone defects. An engineered osseous graft derived from easily 
accessible cell sources, such as the amniotic fluid and the dental pulp, would offer several 
advantages over techniques currently available for the repair of severe bone damages. The 
engineered approach affords much versatility, since a stem cell/scaffold implant can be 
crafted into any shape and size, following the anatomical details of the defect. This study 
evaluated the capability of human stem cells (hAFSCs and hDPSCs) seeded onto fibroin 
scaffolds, in inducing new bone formation in critical size calvaria defects. 
Radiograph and histological analysis revealed that the highest bone formation occurred in 
fibroin, seeded with stem cells committed towards ostegenic lineage, whereas the scaffold 
alone resulted in much lower bone repair. Formation of bone with a very efficient union of 
the new bone with the margins of the defect area occurred after the use of hDPSC or 
hAFSC/fibroin constructs. As a matter of  fact, this implant leaded to a very homogenous 
bone formation process, as both parietal tables are in reconstruction, indicating this as a 
promising approach. The defect was also healed with the use of fibroin only, but the 
ossification process was evidently incomplete when compared to the implant of fibroin 
plus human stem cells. This represents a further evidence of the osteoinductive properties 
of fibroin (Meinel L et al, 2006; Mieszawska AJ et al, 2010; Zhang Y et al, 2011). 
Results obtained in our former study on ectopic implants (Maraldi T et al, 2011) enabled 
us to identify fibroin scaffold as a promising tool for osteogenic differentiation of human 
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stem cells. The present findings demonstrate that fibroin scaffold promotes human stem 
cell proliferation and differentiation in parietal bone graft in a rat experimental model. 
Fibroin scaffold shows a higher biointegration with rat tissues, since a great vascularization 
and the homing of host cells inside the scaffold microenvironment occur. 
Moreover, transplantation of human stem cells in cranial defect model leads to substantial 
increase in bone formation, and the presence of human cells 30 days after implantation 
demonstrates that stem cells, already committed to osteogenic differentiation in vitro, 
finally pilot the bone repair in vivo. Confocal analysis shows ossification areas reflecting 
physiological osteogenesis, since a layer of human cells is distributed on the new bone 
margin, suggesting a bone deposition by osteoblast apposition. At the same time, inside the 
bone synthesis area, human cells are progressively entrapped in lacunae showing a less 
intense staining for anti-human mitochondrial protein ab, indicating a lower metabolic 
activity, as in osteocytes occurs. 
Moreover, this study provides additional insight into the potential use of fibroin scaffolds 
as cell carriers for implantation into skeletal connective tissue defects.  
Mechanical strength is often a prerequisite for scaffolds destined to bone tissue 
engineering; however, most of the materials, although possessing the needed mechanical 
forces, are not optimal for cell growth and differentiation (Ben-David D et al, 2011). A 
major advantage of a mechanically stable scaffold is that it contrasts the deformation 
caused by adjacent tissues at the implant site. This deformation can lead to an implant 
compression within the defect or even a shift beyond the borders of the defect site (Meinel 
L et al, 2006). The data observed in this study indicate that fibroin scaffolds retain a high 
percentage of water maintaining their mechanical properties. Moreover, histological 
analysis demonstrates that fibroin maintains its shape after implant and has been 
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progressively reabsorbed during bone new-synthesis, while remains longer in areas where 
bone deposition may yet occur, according to data previously reported (Meinel L et al, 
2006).  
Taken these considerations, fibroin scaffold seems to be an appropriate solution for bone 
tissue engineering. These findings show that an optimal bone defect repair can be obtained 
by colonizing fibroin scaffold with hDPSCs and hAFSCs, considering that both present the 
advantage of an easy recruitment without ethical problems. Autologous transplantation 
might be performed with both cell types. Human AFSCs could be used in neonatal surgery 
to treat congenital malformations such as the large cranial defects occurring in AC (aplasia 
cutis). Human DPSCs, available mainly from the puberty onward, might be used to heal 
pathologies occurring in the adult life. With respect to other adult stem cell sources, such 
as adipose-derived stem cells, amniotic fluid and dental pulp are tissues largely available 
from routine medical practice and therefore suitable to be collected in stem cell banks in 
order to be employed in both autologous and allogenic transplantations. In fact, both the 
cell types present major histocompatibility complex (MHC) class I, but lack MHC II class 
molecules and seem to have immunosuppressive activity (De Coppi P et al, 2007; Kim J et 
al, 2007; Tsai MS et al, 2004; Pierdomenico L et al, 2005). Further evidence came from 
recents findings demonstrating that MSCs and DPSCs are able to induce T-cells apoptosis 
through Fas/Fas ligand pathway (Akiyama K et al, 2012; Zhao Y et al, 2012) All these 
data indicate that the progenitor cell association with an appropriate scaffold represents an 
optimal tool in many aspects of bone regeneration and tissue engineering applications. 
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2. Human serum is a suitable substitute for FCS to expand and differentiate 
human DPSCs 
The second section of the thesis was aimed to investigate a culture condition that may 
allow human DPSCs for cell-based therapy to be used in clinical application with minimal 
safety concerns. This goal assumes it is desirable and necessary to obtain a sufficient 
number of cells, as the result of expansion and differentiation conditions realized by using 
the most suitable reagents to promote cell proliferation and differentiation.  
Foetal calf serum (FCS) has been widely used for this purpose over the past several 
decades. Anyway, some potential hazards related to the use of FCS in clinical settings have 
been raised in terms of potential disease transmission and xenogenic immunologic 
response (Spees JL et al, 2004). 
Indeed previous works indicate that FCS proteins can be internalized in stem cells and 
involve the hazard of pathogen transmission: bovine proteins may also be recognized as 
antigenic substrates, leading to a xenogenic immune response (Shahdadfar A et al, 2005; 
Dimarakis and Levicar, 2006). For these reasons, in addition to good manufacturing 
practices (GMP), clinical protocols for cell therapy encourage the use of FCS substitute. 
Even serum free media have been tested, but so far literature has demonstrated that these 
media do not constitute an adequate support for proliferation of mesenchymal stem cells, 
without the addition of exogenous growth factors (Lee JW et al, 2004; Foreman MA et al, 
2006). Supplementation of media with small amount of serum and specific factor as EGF 
and PDGF could represent a valid perspective (Karbanová J et al, 2011). 
Various human plasma derivatives have been purposed as alternatives to FCS to supply 
nutrients, adhesion and growth factors. These alternative supplements include autologous 
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or allogenic human serum, human plasma, human platelet lysates and their released factors 
(Schallmoser K et al, 2007; Stute N et al, 2004; Kocaoemer A et al, 2007). In the last years 
platelet-rich plasma was largely used to growth and differentiate MSC but its role in MSC 
osteogenic differentiation is debated (Feng Y et al, 2010; Gruber R et al, 2010; Tomoyasu 
A et al, 2007). The use of human serum, preferably autologous, appears to provide benefits 
for different aspects in culture and differentiation of human synovial MSCs and human 
bone marrow MSCs (Tateishi K et al, 2008; Nimura A et al, 2008; Aldahmash A et al, 
2011). 
Evidence in favour of using autologous serum also exist for the expansion of human bone 
marrow MSCs, indeed it results as effective as supplementing culture medium with FCS, 
and cells appear transcriptionally more stable over many cell doublings (Shahdadfar A et 
al, 2005). Nevertheless, autologous serum may also be a scarcely available or qualitatively 
affected source, particularly in the case it must be taken from some classes of patients, 
such as children, elderly, anaemic and with ongoing inflammatory processes individuals 
(Tateishi K et al, 2008). In these cases, allogenic human serum, potentially from blood 
type AB healthy donors may represent a preferable alternative to autologous serum. 
To date, human platelet lysate and platelet-rich plasma have been shown to be suitable 
culture supplements to replace FCS, for the expansion and in vitro osteogenic 
differentiation of hDPSCs (Lee UL et al, 2011; Govindasamy V et al, 2011).  In literature 
there is not yet evidence that human serum may constitute a suitable replacement to FCS 
for culture and differentiation of human DPSCs. 
This study demonstrates that human serum (HS) is an appropriate supplement for the in 
vitro expansion of human DPSCs, as its addition to culture medium promotes a good 
proliferation rate, comparable to the one measured in culture conditions using FCS. 
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Furthermore, HS increases the hDPSCs doubling during culture, indicating this as an 
optimal condition to obtain a sufficient cell number soon and to consequently reduce the 
waiting for a therapeutical treatment. Otherwise, cells cultured in serum free medium 
showed a growth arrest. Moreover, HS does not induce cell senescence or apoptosis and 
does not affect the surface antigens expression and the multi-lineage differentiation ability 
of hDPSCs. 
The expression of bone related proteins as well as the mineralization of the extracellular 
matrix analyzed in experiments of osteogenic differentiation in vitro indicate that the use 
of HS is adequate to osteogenic differentiation protocols for hDPSCs. 
Moreover HS, compared to FCS, seems to induce a better mineralization of the 
extracellular matrix synthesized by differentiating hDPSCs. 
When transplanted in vivo, in immunocompromised animals, by means of stem cell-
scaffold constructs, hDPSCs pre-differentiated in both the osteogenic media show a 
significant contribution to the regeneration of critical size bone defect. 
Immunofluorescence staining with anti-human mitochondria antibody demonstrates that 
hDPSCs widely contribute to the osteocyte population of the new-formed bone and seem 
to participate to the angiogenetic process that gives rise to endothelial cells of the new-
formed bone. Thus, these findings have demonstrated that human serum represents an 
eligible alternative to FCS, for successful expansion and differentiation of human DPSCs 
towards osteogenic lineage, finding, furthermore, a helpful application for in vivo 
transplantation. 
In particular, the results obtained in vivo allow to propose human serum as additive for 
expansion and differentiation of human DPSCs to be applied in human cell therapy with 
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GMP-compatible protocols. Indeed, it matches with the criteria approved by the 
Committee for medicinal products for human use.  
In this respect, it would be eventually conceivable to develop banks for the storage of 
human cryopreserved stem cells from different sources, which would collect not only stem 
cell samples, but also backup specimens of human serum, both of them obtained from the 
same donors, thus allowing optimal conditions for the expansion and following application 
of human stem cells in clinical cell-based therapies, under compliance with GMP-
compatible methods. 
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3. Skeletal muscle regeneration by human DPSCs and AFSCs 
Duchenne Muscular Distrophy (DMD) is one of the most common (1 in 3500 live male 
births) and severe dystrophies, which occurs with a progressive degeneration of muscle 
fibers and results in death by the third decade of life (Emery and Muntoni, 2003). 
Since the use of corticosteroids only delays the loss of muscle function and at this moment 
a therapy capable to stop the progression of muscle degeneration is lacking (Manzur AY et 
al, 2008), different therapeutic approaches have been tested in order to find the most 
suitable one for treating DMD. 
Cell therapy may be used to reintroduce dystrophin and thus to repair damaged muscle 
fibers. 
Recently, various stem cell lines were used to treat muscular dystrophy, although with 
narrow results. Within the skeletal muscle compartment, other than satellite cells,  many 
adult multi-lineage progenitor cells show a myogenic potential: muscle derived stem cells 
(MDSCs), muscle side population (mSP) cells and muscle derived CD133+ progenitors 
(Qu-Petersen Z et al, 2002; Peault B et al, 2007; Torrente Y et al, 2004). 
Aside from the muscular-resident cells, non-muscular stem cells, from different tissues, 
such as bone marrow, adipose tissue, umbilical cord, placenta, were tested for myogenic 
differentiation capacity (Ferrari G et al 1998; Pinheiro CH et al 2012; Brzóska E et al, 
2006; Kawamichi Y et al, 2010). This thesis evaluated the myogenic potential of human 
dental pulp and amniotic fluid derived stem cells, by using different conditions, such as the 
direct co-culture with murine myoblasts, the use of the DNA demethylating agent 5-Aza-
2’-deoxycytidine, and the addition of conditioned media from differentiated mouse 
myoblasts, with the aim to determine the optimal conditions for achieving the myogenic 
commitment of these human stem cells. 
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Previous studies demonstrated that the genes related to skeletal myogenic differentiation 
are controlled by DNA methylation and that the use of the demethylating agent 5-Aza was 
able to induce adult human bone marrow stem cells to differentiate towards the 
cardiomyogenic lineage (Ye NS et al, 2006; Antonitsis P et al, 2008). 
The results from the direct co-culture of hDPSCs and hAFSCs with C2C12 mouse 
myoblasts have demonstrated that these human stem cells are actually able to participate 
and fuse with mouse myoblasts to form new hybrid myotubes, as clearly shown by the 
positive staining with anti-human Nuclei ab. 
Even more importantly, after being differentiated without direct co-culture, by means of 
DNA demethylation treatment, hDPSCs and hAFSCs underwent myogenic commitment, 
even though myotubes formation was not observed. When conditioned fusion media from 
differentiated C2C12 cells were added to the myogenic medium, a quantitatively higher 
expression of muscle specific factors and markers by hDPSCs and hAFSCs occurred. 
These observations suggest that modulating the myogenic potential of these cells may be 
achieved by combining the demethylation treatment – which triggers the expression of 
those muscle regulatory factors that are fundamental for the myogenesis process – with the 
addition of conditioned fusion media, which contains soluble factors, such as insulin-like 
growth factor II (IGF-II), that have a role in promoting the myogenesis (Duan C et al, 
2010).  
Following the results obtained from the myogenic differentiation in vitro, this study was 
focused on the evaluation of the regenerative potential of hDPSCs and hAFSCs after cell 
injection into the dystrophic skeletal muscle of SCID/mdx mice, the murine model of 
DMD.  
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A good early engraftment was observed within the skeletal muscle fibers of the host, as 
confirmed by the high presence of human cells into the injected muscles, positively 
labelled by anti-hMit ab. This significantly demonstrated that these cells are able to survive 
and be histo-integrated after transplantation in the host tissue. In particular, human DPSCs 
and AFSCs show a direct participation in muscle regeneration as demonstrated by their 
contribution in promoting of new angiogenesis, which is a typical event of tissue 
regeneration processes.  
Furthermore, the regenerative potential of these cells was clearly demonstrated by the 
restoration of dystrophin expression, which shows off as early as 14 days after the cell 
injection and keeps being detected 4 weeks after the transplantation.  
These observations suggest that, once engrafted within the host muscle, human DPSCs and 
AFSCs actively contribute to regenerate the dystrophic skeletal muscles, either by 
promoting the angiogenesis and by restoring the dystrophin expression, that is maintained 
after a relatively long time.  
While from a therapeutic standpoint this research has reached the objective to demonstrate 
the ability of human DPSCs and AFSCs to regenerate the dystrophic skeletal muscle and 
restore the dystrophin expression, a question mark might be raised on whether this is the 
consequence of a cell differentiation or a cell fusion.  
According to the ontogeny, the skeletal muscle development is a tightly regulated process 
involving the specification of mesodermal precursors into myoblasts and following 
differentiation and fusion of these cells into multinucleated myotubes, therefore skeletal 
muscle formation is the result of cells  whose derivation has been definitively established 
to imply cell fusion (Doherty JT et al, 2011; Eisenberg LM and Eisenberg CA, 2003). 
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What was observed in the direct co-culture with C2C12 demonstrates that a clear fusion 
process between human and mouse cells occurred, giving rise to new hybrid 
multinucleated myotubes, even though it was not possible to detect the formation of human 
myotubes, neither when human DPSCs and AFSCs were co-cultured with murine 
myoblasts, nor when when they were differentiated after the demethylating treatment. 
However, the treatment with 5-Aza allowed the human stem cells to be effectively 
committed towards the myogenic lineage, as clearly shown by the immunofluorescence 
microscopy analysis. The detection of human stem cells in the injected dystrophic skeletal 
muscle and, in particular, their presence within muscle fibers with a restored expression of 
dystrophin demonstrate that human DPSCs and AFSCs are able to histo-integrate in the 
muscle microenvironment, but yet preserve their genetic identity over a relatively long 
time, through the maintained expression of dystrophin, otherwise completely lacking in 
dystrophic skeletal muscles.  
In light of these results, it may be reasonable to assume that human DPSCs and AFSCs 
underwent an event that can be defined halfway between the cell differentiation and the 
cell fusion processes.  
Therefore, human DPSCs and AFSCs may be considered a suitable tool that could be very 
useful for translational strategies aimed to enhance the repair of injured skeletal muscle in 
DMD or trauma patients, besides representing an effective means to promote new 
vascularisation of different tissues.  
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Conclusions 
This thesis has highlighted the properties and the differentiation abilities of human dental 
pulp and amniotic fluid stem cells, that allow to propose them as a suitable non-
controversial source of stem cells, for the application in regenerative medicine of different 
tissues.  
With regard to the bone regeneration, the effective differentiation potential towards the 
osteogenic lineage shown by hDPSCs and hAFSCs is confirmed when these human stem 
cells are combined to fibroin scaffold in stem cells-scaffold complexes aimed to heal 
critical size bone defects in vivo; indeed, the three-dimensional structure of this fibroin 
support has shown to be an optimal microenvironment for the osteogenic differentiation of 
these human stem cells and for the subsequent bone tissue regeneration.  
These results suggest the eventual applicability of human DPSCs and AFSCs for 
autologous transplants.  Moreover, the need for development of optimal culture conditions 
without the use of animal products for future applications of cell therapy to humans, has 
leaded the research to investigate alternative human derivatives as supplements to culture 
and differentiation media for mesenchymal stem cells.  
The results obtained in this study demonstrate that human serum not only promotes a good 
proliferation rate, but also increases the cell doubling during culture, does not induce cell 
senescence or apoptosis and does not affect either the expression of stemness surface 
antigens and the multi-differentiation ability in vitro. The mineralization of the 
extracellular matrix observed in the experiments of osteogenic differentiation in vitro 
indicate that the use of human serum is adequate to hDPSCs osteogenic differentiation 
protocols. The subsequent results have confirmed the successful use of human serum for 
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pre-differentiating of hDPSCs to be transplanted in vivo for the regeneration of critical size 
bone defects, by means of a stem cell-scaffold construct.  
This study has also demonstrated that human dental pulp and amniotic fluid stem cells 
have the capability to be committed towards the myogenic lineage in vitro and to actively 
regenerate the skeletal dystrophic muscle of SCID/mdx mice, in particular by restoring the 
expression of dystrophin.  
Moreover, human DPSCs and AFSCs have shown a high contribution in promoting new 
angiogenesis of the tissues in which they were implanted in vivo, an event that has never 
been implicated with tumorigenic processes in the experiments carried out so far.  
Altogether these data allow to propose these two types of human stem cells for a future 
potential application in regenerative medicine of different tissue injuries, following 
traumas and diseases. 
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